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Identification of functional and expression polymorphisms associated with risk for  
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Objective: To identify risk alleles relevant to the cause and biology of anti-neutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis (AAV). 
Methods: We conducted a genome-wide association and subsequent replication study including 
1986 cases of AAV [granulomatosis with polyangiitis (GPA) or microscopic polyangiitis 
(MPA)] and 4723 controls. Meta-analysis of these datasets and functional annotation of 
identified risk loci were performed and candidate disease variants with unknown functional 
effects investigated for impact on gene expression and/or protein function. 
Results: Among the genome-wide significant associations identified, the largest effect on risk 
came from rs141530235 and rs1042169 SNP variants at the HLA-DPB1 locus (odds ratios = 2.99 
and 2.82, respectively) which, together with a third (rs386699872) variant, constitute a triallelic 
risk haplotype associated with reduced HLA-DPB1 gene and HLA-DP protein expression in B 
cells and monocytes and with increased frequency of complementary proteinase-3-reactive T 
cells relative to levels in protective haplotype carriers. Significant associations were also 
observed at the SERPINA1 and PTPN22 loci, the peak signals arising from functionally-relevant 
missense variants, and at PRTN3, where the top-scoring variant correlated with increased PRTN3 
expression in neutrophils. Effects of individual loci on risk differed in patients with GPA versus 
MPA or proteinase-3 versus myeloperoxidase-ANCA, but the collective population attributable 
fraction for these variants was substantive (77%).  
Conclusion: This study reveals the association of GPA and MPA susceptibility with functional 
gene variants that explain much of the genetic etiology of AAV, influence and possibly predict 
clinical presentation, and alter immune cell proteins and responses likely key to disease 
etiopathogenesis. 
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Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threating 
necrotizing vasculitides strongly associated with the presence of anti-neutrophil cytoplasmic 
antibodies (ANCA) reactive to proteinase-3 (PR3) or myeloperoxidase (MPO). Although often 
considered a single disease, GPA and MPA diverge in important respects, such as the extent of 
their association with PR3-reactive versus MPO-reactive ANCA, risk of relapsing disease, and 
GPA association with granulomatosis inflammation. The etiology of AAV remains unknown; 
however, genome-wide association studies (GWAS) performed in a North American GPA cohort 
and a European GPA/MPA cohort confirmed candidate gene analyses identifying strong 
association of these diseases with MHC class II region alleles (1, 2). A genome-significant 
association at the SERPINA1 locus was also identified in the European study, with this and 
several MHC associations differentially detected in patient subsets defined by presence of PR3 
or MPO-ANCA (2). These findings have not yet been replicated and knowledge remains 
rudimentary regarding the non-MHC loci and specific disease-causal variants predisposing to 
GPA and/or MPA. Therefore, we sought to further define the genetic variation underpinning 
GPA and MPA susceptibility by conducting a new GWAS and validation study of a larger, 
independently-ascertained North American-based cohort of GPA/MPA patients and healthy 
controls and using functional annotation of the risk loci to identify candidate disease-causal 
alleles.  
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All study subjects were of self-reported European ancestry, with the diagnosis of AAV and GPA 
or MPA based on modified ACR criteria for classifying vasculitis (3). The discovery cohort 
included: 779 cases recruited via 13 centers from the Vasculitis Clinical Research Consortium 
(VCRC), which conducts studies involving vasculitis patients followed in the USA, Canada and 
elsewhere; 438 cases recruited via the Wegener’s Granulomatosis Genetic Repository 
(WGGER), a study conducted at 8 centers in the USA from 2001 to 2005; and 378 cases from 
the University of North Carolina Kidney Center. Key clinical and serological features for the 
cases are provided in Supplementary Table 3. The controls included 202 healthy subjects 
recruited via WGGER and 3121 historic controls whose genotype data were obtained from the 
Resource for Genetic Epidemiology Research on Aging study (4, 5). The replication cohort 
included 505 AAV cases and 1477 healthy controls recruited independently from Canada and the 
USA via a Toronto-based AAV study and 114 independent cases recruited via the VCRC. 
Demographic data, peripheral blood cells and/or saliva samples were obtained with written 
informed consent as approved by the local institutional review board.  
 
Genotyping methods 
For the GWAS, 1615 cases of AAV and 202 controls were genotyped at the Mount Sinai 
Hospital Clinical Genomics Centre and 3121 “historic” controls were genotyped at Affymetrix 
(Santa Cruz, CA) using the Axiom Biobank 1 Genotyping array. This array tests 628,679 SNPs, 
including 246,000 (36.5%) genome-wide association markers, 265,000 (39.3%) non-
synonymous coding SNPs, 70,000 (10.4%) loss-of-function SNPs, 23,000 (3.4%) eQTL SNPs, 
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2,000 (0.3%) pharmacogenetic markers, and 27,679 “custom” markers. Genotypes were called 
and processed using Affymetrix Genotyping Console
TM
 4.2 and SNPolisher software. Quality 
control filtering was performed using Golden Helix SVS 8.3.4 software and genotype call rate 
> 95%, individual sample call rate > 97% and exclusion of SNPs with Hardy-Weinberg 
equilibrium (HWE) p-value < 10
-5
. After filtering, genotypes derived from SNP markers 
common to both datasets were merged in a single file containing 1528 cases, 3309 controls and 
333,040 SNPs. A set of LD-pruned SNPs with MAF > 5% was used to estimate identity by 
descent (IBD) and ancestry. For each pair of individuals with an estimated IBD of > 0.25, the 
sample with the lower call rate was removed. Principal-component analysis (PCA) was used to 
exclude samples of non-European ancestry (6). In total, 1371 cases, 3258 controls, and 333,035 
SNPs passed quality control filters (Supplementary Figure 1).  
 
For the replication study, 8 SNPs in 6 gene loci were genotyped in 619 AAV cases and 1477 
controls using Sequenom iPLEX assays. One other SNP (rs62132293) at the PRTN3 locus was 
genotyped using Taqman (Applied Biosystems). After quality control filtering, 615 cases, 1465 
controls, and 9 SNPs were retained for analysis. For the replication study of the MPO-
ANCA/perinuclear ANCA (designated here as MPO-ANCA) subgroup, three additional SNPs 
(rs3998159, rs7454108 and rs1049072) at the HLA-DQA2 and -DQB1 loci were genotyped on 
the same platform. GWAS and replication datasets were then combined for meta-analysis. 
 
Statistical methods 
Association and meta-analyses. For the discovery dataset, case-control association tests were 
conducted using logistic regression with principal components differing between cases and 
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controls included as covariates to adjust for population stratification. Calculation of the genomic 
control factor using EIGENSTRAT showed minimal inflation, 1.012 and 0.991, respectively, 
before and after adjustment for the top three eigenvectors (Supplementary Figure 2). An analysis 
of all the nonzero eigenvalues established that 221,341 independent tests were conducted from 
280,677 autosomal markers which, with Bonferroni correction, established the p value for 
genome-wide significance as < 2.2x10
-7
. Meta-analysis of the data from the GWAS and 
replication logistic regression analyses was conducted using the basic meta-analysis function in 
PLINK v1.9 (6, 7). Differences between GPA and MPA and PR3-ANCA/cytoplasmic ANCA 
(hereinafter PR3-ANCA) and MPO-ANCA case groups were studied using this approach. 
Between-study heterogeneity was tested by the χ
2
-based Cochrane's Q statistic.  Heritability was 
estimated using GCTA as described by Lee et al (8) and assuming an AAV prevalence of 
1/10,000. Prior to analysis we excluded sex chromosome data, SNPs with MAFs <0.05 and 
missing rates >0.01, individuals whose missing SNP rates were>0.01, SNPs with an HWE p-
value <0.05 or markers with a significant difference in missingess between cases and controls.  
Imputation. Genome-wide imputation for the 4629 samples in the discovery cohort was 
performed using 1000 Genomes Project Phase 3 data as the reference (release date October 
2014) for the autosomes and Phase 1 data (release date August 2012) for the X chromosome. 
Following removal of SNPs with call rates <95%, MAF <0.001 and HWE p values < 10
-5
, 
SHAPEIT (shapeit.v2.r790.Ubuntu_12.04.4.static) was used to derive phased genotypes and the 
phased data imputed using IMPUTEv2 (impute_v2.3.2_x86_64_static) to assess ~5Mb non-
overlapping intervals (9). Imputation within defined regions was performed using IMPUTEv2 
without prephasing.  
 
Page 8 of 69
John Wiley & Sons
Arthritis & Rheumatology












Conditional Analysis. To test for multiple independent effects within the HLA region, a logistic 
regression framework was used to assess individual HLA alleles for association, including the 
top 3 principal components as covariates to account for population stratification. After 
identifying the most significant marker, we tested for additional independent effects by including 
the dosage of the top markers in a joint model. Conditional analysis was performed using the 
proc logistic module of SAS version 9.2 to obtain odds ratios (ORs) when all top markers were 
jointly analyzed. 
 
Population Attributable Fraction (PAF). PAF was estimated using ORs from a multivariate 
logistic regression model incorporating SNPs from multiple loci so that each OR is adjusted for 
the effects of the other SNPs. PAF for effects from an allele at a single locus was set as: 
 = ( − 1)1 + ( − 1) 
where OR is the odds ratio associated with the allele genotype and RAF is the allele frequency of 
the risk variant. For computation over multiple loci, this formula becomes:  





Random Forest Analysis. The potential role for combinations of alleles in risk for AAV was 
evaluated by random forest analysis using classification and regression tree (CART) 
methodology (10). Data from 11 risk-associated variants were subjected to analysis in which 
CARTs were repetitively built using two-thirds of the samples and variables and used to classify 
the remaining one-third of the data. Eight variants that improved the model fit by ≥ 3% were 
retained to build a CART. The rpart program in R and the Gini index measure were used to 
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identify optimal splits of the data, with the complexity parameter set to 0.001 and the data then 
pruned to include only those nodes containing at least 20 observations. This final model had a 
classification accuracy of 73%. ORs were calculated with:  = #			 # !"			##			$ # !"			$#  
and used the Woolf approximation to compute standard errors and confidence intervals. 
 
Functional annotation. The online Probabilistic Identification of Causal SNPs (PICS) algorithm 
(http://www.broadinstitute.org/pubs/finemapping/?q=pics) was used to identify variants at each 
risk locus with a PICS probability (>0.0275) consistent with that used by Farh et al (11). We then 
used the Ensembl Variant Effect Predictor web tool to annotate these variants for predicted 
functional consequences (http://www.ensembl.org/info/docs/tools/vep/index.html) and Genevar 
(12), seeQTL (http://www.bios.unc.edu/research/genomic_software/seeQTL/) (13) and the 
University of Chicago eQTL browser (http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/) to identify 
expression quantitative trait loci (eQTLs). 
 
Cellular assays 
Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear leukocytes were isolated 
over Ficoll-Hypaque from patients followed at MSH. For quantitative PCR (qPCR), RNA 
(500ng) was reverse transcribed using random hexamer primer and SuperScriptIII reverse 
transcriptase (Invitrogen) and qPCR performed using SYBR green and the gene appropriate 
primer pairs (Supplementary Table 1). Samples were run on an ABI PRISM 7900 HT system 
(Applied Biosystems) and the fold change in expression of the specific gene relative to the 
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For flow cytometry, PMBCs stained with phycoerythrin anti-CD19, APC-Cy7-anti-CD14 (BD 
Biosciences) and/or FITC-HLA-DP (Leinco) antibodies or FITC-conjugated murine IgG (BD 
Biosciences) were analyzed using the FACS Canto cytometer (BD Biosciences) and FlowJo 
software. 
 
For ELISPOT experiments, 20mer peptides selected using published data or the NetMHCII 2.2 
prediction algorithm (www.cbs.dtu.dk) were synthesized and purified by the manufacturer 






from PR3-ANCA vasculitis patients and healthy controls were suspended in 
20% FBS-supplemented RPMI and incubated in 96-well ELISPOT plates (Millipore) pre-coated 
with anti-human IFN-γ monoclonal antibody (eBioscience). Cells were stimulated for 24 hours at 
37°C with 10µg/ml peptide or 1µg/ml ConA (Sigma) and incubated with biotinylated mouse 
anti-human IFN-γ antibody (eBioscience), avidin-HRP (eBioscience) and AEC solution (BD
TM
 




Identifying GPA/MPA susceptibility loci 
After filtering and correction for population substructure, our GWAS discovery dataset included 
333,035 SNPs genotyped in 1,371 cases of AAV (GPA and MPA) and 3,258 healthy controls 
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with no evidence of inflation of the test statistic (λGC=0.991) (Supplementary: Methods, Figures 
1 and 2, and Table 3).   
 
Association analysis of this cohort identified 120 SNPs across the MHC class II locus achieving 
genome-wide significance levels, the strongest signals emanating from the DPB1, DPA1, DQA1, 
and DQB1 genes (Table 1 and Supplementary Table 4). Four other SNPs across three non-MHC 
gene loci also achieved genome-wide significance levels and were taken forward together with 
five top-scoring SNPs from the MHC region for a replication study in an independent cohort of 
615 cases and 1,465 controls (Table 1, Supplementary Figure 1 and Table 3). As all associations 
tested were replicated (P ≤ 0.05 threshold), the GWAS and replication datasets were combined 
for a meta-analysis and the nine associations also explored in patient subgroups defined by GPA 
or MPA phenotypes or ANCA specificities and/or immunofluorescence patterns (PR3-ANCA or 
MPO-ANCA).   
 
Results of the meta-analysis confirmed the MHC class II region as the locus most strongly 
associated with AAV susceptibility (Table 1). The peak association signals arose from two HLA-
DPB1 gene variants, rs141530233 (P=1.13x10
-89
) and rs1042169 (P=1.12x10
-84
), with other 
significant associations observed in the HLA-DPA1¸DQA1 and DQB1 genes (Table 1, 
Supplementary Figures 3 and 4). Associations with DPA1 and DPB1 remained strong in the 
GPA and PR3-ANCA subgroups, but not in the MPA or MPO-ANCA subgroups. Conversely, 
the DQB1 association was much stronger in the MPO-ANCA relative to PR3-ANCA subgroup 
(Table 2A). In view of this divergence, GWAS, replication, and meta-analysis were also 
performed de novo comparing patients with either PR3-ANCA or MPO-ANCA to controls. 
Page 12 of 69
John Wiley & Sons
Arthritis & Rheumatology












These analyses revealed significant association of the MPO-ANCA phenotype with rs3998159 
(P=5.24x10
-25
) and rs7454108 (P=5.03x10
-25
) variants at the HLA-DQA2 locus (Table 2B, 
Supplementary Table 6). Neither this nor any other significant associations beyond those 
detected in the AAV GWAS were detected in the GWAS of PR3-ANCA cases and controls 
(Supplementary Table 5). 
 
Among the non-MHC associations identified in the AAV GWAS, the strongest signal arose from 
a SNP (rs28929474) in the SERPINA1 gene (P=3.09x10
-12
) encoding an α1 anti-trypsin null 
(“Z”) allele implicated previously in GPA by candidate gene analysis (Table 1, Supplementary 
Figures 3 and 4) (15). This association was limited to the GPA and PR3-ANCA subsets (Table 
2A) and is consistent with prior GWAS data showing that a significant association with another 
SERPINA1 SNP (rs7151526) depended entirely on concomitant presence of the Z allele (2).  
 
A significant association of AAV (P = 8.60 x 10
-11
) with rs62132293, a SNP located 2.6kb 
upstream of the PRTN3 transcription start site, was also observed and is in keeping with prior 
associations (albeit with different SNPs) at this locus identified by AAV candidate gene and 
GWAS analyses (Table 1, Supplementary Figures 3 and 4) (2, 16). This association was limited 
to the GPA and PR3-ANCA subsets (Table 2A), consistent with pathophysiologic relevance of 
the PRTN3-encoded proteinase 3 serine protease (PR3) to these phenotypes (17).  
 





, respectively) (Table 1, Supplementary Figures 3 and 4). Consistent 
with their equivalent effect sizes, these variants are in almost complete LD (r
2
=0.99). However, 
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the rs2476601 variant encodes an Arg620Trp substitution in the Lyp phosphatase associated with 
risk for multiple autoimmune diseases, including giant cell arteritis (18, 19). Although variably 
observed in candidate gene studies (20, 21), this allele’s association with GPA/MPA is strongly 
supported by our data and, unlike most other significant associations, did not differ between 
subgroups (Table 2A). 
 
Possibly reflecting the analysis of a different case/control cohort, the discovery GWAS of either 
the entire cohort or the PR3-ANCA subgroup revealed no reliable associations at the SEMA6A 
gene locus. In the current discovery GWAS, there were 189 SNPs in the 1 MB region around 
SEMA6A from which the most significant variant (rs12521259) is ~100kb upstream of SEMA6A, 
with p=9.11x10
-3
 in the full cohort and p=4.87x10
-3
 in the PR3 ANCA subgroup.  
 
Analyses of the associations in patient subgroups defined by presence or absence of lung or 
kidney disease revealed a modest association (P=8.15x10
-3
) at the HLA-DPA1 locus restricted to 
patients with kidney involvement; no significant subgroup differences were apparent at the other 
risk loci (Supplementary Table 7). A modest restriction of the HLA-DPB1 and HLA-DPA1 
association to ANCA-positive patients was observed, but may reflect the relatively low numbers 
of ANCA-negative cases analyzed.  
 
Risk alleles contribute jointly to disease susceptibility 
As the strongest associations in all subgroups were with MHC gene SNPs, independence of the 
individual allele associations was explored by forward logistic regression selection analysis. 
Beginning with the most significant SNP identified in the total cohort or in the PR3-ANCA or 
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MPO-ANCA subgroups, additional significant variants were incorporated into the analysis until 
no variants significant at the P<5x10
-8
 level remained. This analysis (Supplementary Table 8) 
revealed variants in several of the class II genes studied in each group to be jointly significantly 
associated with risk. 
 
Results showed the array heritability of AAV was 0.2197 + 0.0204, while with the HLA region 
removed, was 0.138 + 0.022. The population attributable fraction (PAF) for the risk loci to 
disease was also assessed and the collective contribution of these loci to risk for AAV found to 
be substantive (PAF = 77%), albeit variable (PAFs between 30% and 87%) across different 
subgroups (Table 3). 
 
The extent to which the risk variants/variant combinations predict disease was also evaluated 
using random forest and classification and regression tree (CART) methods. These analyses 
confirmed the strong association of HLA class II alleles with risk (Supplementary Figure 6), with 
homozygosity for the relatively common DPB1 rs141530233 and DPA1 rs9277341 risk alleles 
together with homozygosity or heterozygosity for the rare SERPINA1 risk variant (rs2829474) 
identifying a subgroup with an OR > 10 for developing AAV. For HLA alleles, no subsets were 
defined by heterozygotes and further modeling comparing the goodness-of-fit of additive, 
dominant and recessive models showed that risk imbued by the HLA-DPB1, DPA1 and DQA1 
disease-associated variants is recessively inherited, i.e. conferred by carriage of the common 
homozygous genotypes (Supplementary Table 9). The ORs associated with homozygous risk 
genotypes were 3.58 for rs141530233, 2.69 for rs9277341 and 1.80 for rs352425282. Similar 
results were found for the subgroups defined by carriage of PR3- or MPO-ANCA with recessive 
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models fitting best. These observations suggest the potential for genetic data to inform the 
distinction of patient subsets within the AAV population and identify an unusual recessive effect 
for the HLA region loci studied.  
 
The disease-associated PRTN3 polymorphism is a novel eQTL 
To identify candidate causal variants, additional genotypes were imputed and the PICS algorithm 
applied across each risk locus (11). Although peak association signals at a few loci were stronger 
for imputed than observed SNPs (Supplementary Table 10), among all variants with PICS 
probability >0.0275, the index SNPs derived from direct genotyping were consistently associated 
with the highest PICS values (Supplementary Table 11). PICS values were particularly high for 
the index SNPs at the HLA-DPB1, SERPINA1, and PTPN22 loci, which are all functional 
missense variants (15, 22, 23). The candidate causal variants at the other HLA gene loci were 
either synonymous, intronic, or upstream gene variants, but the majority of these noncoding and 
even several HLA-DPB1 coding variants have been annotated as expression quantitative trait loci 
(eQTL) influencing gene expression in immune cell lineages (24). 
 
None of the candidate variants at the PRTN3 locus were coding or reported eQTL SNPs. 
Increases in PRTN3 expression levels have, however, been observed in AAV patient neutrophils 
and implicated in pathogenicity (17, 25). As knowledge of neutrophil-specific eQTLs remains 
limited, we evaluated the lead SNP at this locus (rs62132293) for allelic effects on PRTN3 
expression in neutrophils. Results of qPCR analyses revealed cellular PRTN3 transcript levels to 
be significantly higher in risk (G) allele homozygotes than in donors with CC or CG genotypes 
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(Figure 1). These results identify rs62132293 SNP as an eQTL for PRTN3 and suggest that the 
causal variant at this locus engenders risk by its association with increased PRTN3 expression. 
 
The rs141530233 risk variant is associated with altered HLA-DPB1 expression and T cell 
responses 
Among the candidate causal variants, the HLA-DPB1 rs141530233 and rs1042169 SNPs had the 
largest effects on risk, with respective ORs of 2.99 and 2.82 in the primary cohort and 6.19 and 
6.09 in the PR3-ANCA subset (Tables 1 and 2A). These SNPs are, respectively, 
insertion/deletion (-/A) and missense (G/A) polymorphisms that map only two base pairs apart in 
exon 2 of the HLA-DPB1 gene, with their risk alleles in complete LD in the control cohort and 
the reference 1000 Genomes Project datasets. In the latter population, these alleles correlate 
perfectly with another insertion/deletion polymorphic variant (rs386699872 CA/G) three base 
pairs downstream of rs141530233, suggesting that these variants comprise a triallelic risk and 
non-risk HLA-DPB1 haplotype (Supplementary Figure 5). To confirm the haplotypic relatedness 
of the three variants, we sequenced this region in 100 study subjects homozygous for the 
rs141530233 and rs1042169 markers. Our findings confirmed the organization of the three 
variants in two haplotype blocks (Supplementary Figure 5), in keeping with prior reports of a 
dimorphic polymorphism (GGPM versus DEAV) at the corresponding amino acid positions (84-
87) of the HLA-DPB chain (22, 26, 27).  
 
Effects of the rs141530233 SNP on gene expression have not been reported, but the linked 
missense rs1042169 G/A SNP has been catalogued as an eQTL with the homozygous GG 
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genotype correlated to increased HLA-DPB1 expression in peripheral blood mononuclear cells 
(PBMCs) (24). These variants are in LD with a SNP variant in the downstream HLA-DPB1 3ꞌ 
UTR (rs9277534) for which the homozygous genotype is associated with lower levels of HLA-
DPB1 and HLA-DP expression in immune cells compared to the alternate homozygous genotype 
(28, 29). We therefore assessed the relationship between the triallelic AAV risk haplotype and 
HLA-DPB1/HLA-DP expression using PBMCs from healthy subjects carrying risk or protective 
rs1042169 alleles. Results of qPCR analysis revealed HLA-DPB1 mRNA levels to be 
significantly lower in rs1042169 GG risk allele homozygotes than in subjects with AA or GA 
genotypes (Figure 2A). Flow cytometric analyses revealed significantly lower HLA-DP 
expression on CD19
+
 B cells and CD14
+
 monocytes from GG donors than on cells from GA or 
AA subjects (Figures 2B and 2C). Thus, the triallelic risk haplotype defined by the rs104216 G 
variant is associated with reduced HLA-DPB1 transcript and HLA-DP surface expression in 
immune cells. 
 
The finding that a triallelic haplotype correlated to reduced HLA-DPB1/HLA-DP expression and 
encoding a putative functionally important HLA-DP polymorphism is highly associated with risk 
for AAV and particularly PR3-ANCA vasculitis strongly suggests that this genetic variation 
influences HLA-DP-modulated immune responses relevant to susceptibility. Because T cells that 
respond to PR3 protein or peptides have been identified in patients with PR3-ANCA AAV and 
the frequency of T cells responding to a “complementary” peptide encoding anti-sense PR3 
codons (cPR3) has been correlated with the presence and activity of disease (30-35), we 
stimulated PBMCs from patients carrying rs1042169 G and/or A alleles with putatively 
immunogenic cPR3 and PR3 peptides and used an interferon-γ ELISPOT assay to identify 
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responding T cells. While the PR3 peptides elicited either no or minimal responses (data not 
shown), in most patients the cPR3 peptide evoked clear reactivity that was completely absent in 
cells stimulated with an irrelevant (OXY) peptide (Figure 2D) and in cells from healthy controls 
(data not shown). Frequencies of IFN-γ-producing cells differed strikingly among patients 
depending on rs1042169 allele status, numbers of responding T cells being significantly higher 
(P < 0.020) in risk allele homozygotes than in individuals having one or two copies of the 
protective A allele and significantly higher in risk allele homozygotes following cPR3 compared 
to OXY stimulation (P < 0.0064). These findings are in keeping with presence of cPR3-reactive 
T cells in PR3-ANCA vasculitis patients and the possibility that altered HLA-DP expression and 
possibly function associated with the HLA-DPB1 homozygous risk haplotype correlate with 
increased numbers of autoreactive cells. 
 
DISCUSSION 
This study identifies MHC and non-MHC gene variants associated with GPA/MPA susceptibility 
and altered gene expression and/or function of proteins integral to immune responses. Our data 
reveal that the largest effect on risk emanates from a triallelic HLA-DPB1 haplotype 
underpinning a previously-reported HLA-DPB amino acid polymorphism across positions 84-87 
(22-27). Our data also support major roles for the PRTN3, SERPINA1, and PTPN22 genes in 
AAV susceptibility, providing the first evidence for genome-wide significant association with 
the PTPN22 rs2476601 functional variant and identifying the top-scoring variant at SERPINA1 
as a null allele and at PRTN3 as an eQTL allele correlated with increased PRTN3 expression in 
neutrophils. Results of CART analysis reveal the potential for these functional variants to 
identify population subsets at highly elevated risk for GPA/MPA, consistent with their collective 
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PAF of 77%. The estimated array heritability of 21% is comparable to estimates for 
inflammatory bowel disease (36).    
 
Among the MHC associations, the HLA-DPB1 risk haplotype alleles appear particularly 
significant, having a very strong effect on risk and underpinning a beta chain polymorphism in 
the HLA-DP antigen-binding pocket that modulates the protein’s peptide-binding properties and 
possibly its effects on T cell allorecognition (22). This haplotype’s physiologic significance is 
also implied by our data linking these risk alleles to decreased HLA-DPB1 and HLA-DP 
expression and increased frequency of cPR3 peptide-reactive T cells in patients with anti-PR3 
autoantibodies. Although understanding of the autoantigenic epitopes driving T cell responses in 
AAV is limited, our findings are consistent with prior data correlating alleles at linked HLA-
DPB1 SNP loci to differential HLA-DPB1/HLA-DP expression and with the association of such 
expression changes as well as the HLA-DP GGPM/DEAV variance with differential outcomes of 
specific immune challenges (28, 29). Further investigation is required to define the extent to 
which the risk haplotype associated increase in autoreactive T cells reflects the failure to 
eliminate such cells during thymic selection and/or another mechanistic aberrancy. 
 
Among the non-MHC associations identified, direct causal effects of the PTPN22 risk variant are 
strongly suggested by data linking the associated Lyp variant to aberrant increases in lymphocyte 
antigen receptor signaling and dendritic cell activation (23). Direct contribution of the 
SERPINA1 rs28929474 risk variant to pathogenesis is also implied by the established role for 
alpha 1-antitrypsin in inhibiting PR3 protease activity and, by extension, PR3-induced 
inflammatory responses (37). Similarly, the most strongly associated PRTN3 variant increases 
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neutrophil PRTN3 expression, an aberrancy found often in PR3-ANCA positive patients and 
correlated with pathogenic neutrophil activation, suggesting that altered PRTN3 expression 
mediated via this or a tightly-linked variant(s) functionally underpins the PRTN3 association 
with AAV (17, 38). 
 
Our analyses revealed risk for the various AAV phenotypes to be linked to joint effects of 
different genes across the HLA class II region. Consistent with a prior report of genetic 
distinctions between PR3-ANCA and MPO-ANCA vasculitis (2), we detected peak associations 
with HLA-DPB1 and HLA-DPA1 variants in the former, but with HLA-DQA2 and HLA-DQB1 
variants, in the latter subgroup. Differential effects of these variants also distinguished GPA from 
MPA patients, suggesting that GPA and PR3-ANCA AAV share a composite of MHC class II 
risk alleles that is largely distinct from those conferring risk for MPA and MPO-ANCA AAV. 
Stronger associations at the PRTN3 and SERPINA1 loci appear to distinguish the GPA and PR3-
ANCA subsets from their counterpart subgroups. By contrast, effects of the PTPN22 locus on 
risk seem equivalent across the different subsets, suggesting the genetic disparities between 
subgroups do not reflect insufficient statistical power and are important determinants of 
phenotypic heterogeneity in AAV.  
 
In summary, our study has illuminated MHC and non-MHC gene variants that are strongly 
associated with AAV, differentially associated with key clinical and serological disease subsets, 
and potentially directly influencing pathogenesis. The extent to which and mechanisms whereby 
these variants directly cause disease requires more investigation, our data not precluding biologic 
relevance of other alleles in LD with these variants, particularly at the HLA-DPB1 and PRTN3 
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loci. Whether sample size constrained analysis of important subsets (such as patients with IgG 
versus IgA ANCA) or confounded detection of some important associations remains to be 
determined (39). Nonetheless, our findings identify a set of risk variants that explain much of the 
genetic risk for GPA/MPA, appear to influence clinical presentation of disease, and represent 
biologically important alleles with high potential to drive the aberrant immune responses 
contributing to development of AAV. 
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Figure 1. AAV-associated rs62132293 variant is associated with increases in PRTN3 
expression. PRTN3 mRNA levels were detected by qPCR amplification of cDNA from 
peripheral blood polymorphic nuclear leukocytes of healthy donors with rs62132293 CC (n = 7), 
rs62132293 CG (n = 9) or rs62132293 GG (n = 6) genotypes. PRTN3 expression levels relative 
to the calibrator reference gene COX5B are presented as normalized individual data points in 
box-and-whisker plots. AAV = ANCA-associated vasculitis. The horizontal line within each box 
indicates the median expression value; vertical lines indicate lowest and highest data points. Data 
are representative of 3 independent experiments. P value shown for unpaired t test. 
 
Figure 2. rs1042169 alleles are associated with differential HLA-DPB1 expression and T 
cell responses. (A) HLA-DPB1 mRNA levels were detected by qPCR amplification of cDNA 
from PBMCs of healthy donors with rs1042169 GG (n=13), rs1042169 AA (n=7) or rs1042169 
GA (n=8) genotypes. HLA-DPB1 mRNA levels relative to the calibrator reference gene GAPDH 
are shown in box-and-whisker plots; horizontal line indicates median expression value and 
vertical lines indicate lowest and highest data points. Data are representative of 3 independent 
experiments. (B, C) Surface HLA-DP levels were evaluated in B cells (B) and monocytes (C) by 
flow cytometric assays of anti-DP and anti-CD19 or anti-CD14 antibody stained PBMCs from 
rs1042169 GG (n=24), rs1042169 AA (n=5), or rs1042169 GA (n=9) donors. Black bars show 
average mean fluorescence intensity (MFI) values. (D) PBMCs from PR3 ANCA
+
 patients with 
rs10421699 GG (n=21), AA/AG (n=8) genotypes were stimulated with anti-sense PR3 cPR3 or 
OXY control peptide and analyzed for IFNγ-secreting T cells by ELISPOT (data indicate mean 
fold change of stimulated versus unstimulated cells). Bars show the mean ± SEM. Significant P 
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values shown for unpaired t test (A-C), Mann-Whitney U test (D: GG vs AA/AG + cPR3
138
), and 
Wilcoxon signed-rank test (D: GG cPR3
138




Supplementary Figure 1. Quality Control and Study Design. AAV = ANCA-associated 
vasculitis; GERA = Genetic Epidemiology Research on Aging; VCRC = Vasculitis Clinical 
Research Consortium; WGGER = Wegener's Granulomatosis Genetic Repository; UNC = 
University of North Carolina. Panel A shows the outcomes of genotyping quality control for 
single nucleotide polymorphisms (SNPs) and genomic DNA from individual subjects. The 
requirements for SNPs to meet quality control standards were call rates of greater than 95%, p < 
1 x 10
-5
 for test of Hardy-Weinberg equilibrium and >0.01 for test of minor allele frequency. 
Panel B shows the numbers of cases and controls used in the discovery (GWAS) and replication 
cohorts and combined to generate a meta-analysis data set. 
 
Supplementary Figure 2. Quantile-Quantile plot of test statistics for the genome-wide 
association study. The –log10(p) values from EIGENSTRAT analysis are plotted on the Y axis 
against the expected –log10(p) values on the X axis after removing all individuals and SNPs that 
failed quality control. After genomic control correction, the inflation factor was λ = 0.991 with 
and 1.012 without eigenvector adjustment. (A) –log10(p) values for all GWAS SNPs. (B) –
log10(p) values after removal of the HLA region SNPs. 
 
Supplementary Figure 3. Results of  the ANCA-associated vasculitis genome-wide 
association screen. The Y axis shows the –log10P values (from EIGENSTRAT) for each single 
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nucleotide polymorphism on each chromosome along the X axis. The dashed line indicates the 




Supplementary Figure 4. Locus Zoom plots. Showing regional associations across the MHC 
and non-MHC loci. The –log10P values of single-nucleotide polymorphisms genotyped in the 
discovery (●) and replication (▲) cohorts and included in the meta-analysis (♦) are plotted 
against their chromosomal position at each locus. SNPs are coloured depending on their degree 
of correlation (r
2
) with the top SNP (as estimated on the basis of 1000 Genome European 
haplotypes, 2012) shown in purple. Genes and expressed sequence tags within each region are 
shown in the lower panels. HLA-DP and DQ regions; PTPN22; PRTN3 and SERPINA1. 
 
Supplementary Figure 5. Confirmation of triallelic HLA-DPB1 risk and non-risk 
haplotypes by direct sequencing analysis. Sequence analysis showing the HLA-DPB1 exon 2 
region rs1042169, rs141530233, rs386699872 risk and non-risk haplotypes. A 201 bp segment 
across HLA-DPB1 nucleotide positions 3,048,604 to 33,048,804 (GRCh37/hg19) was PCR 
amplified using primer pairs 5’-GAGTACTGGAACAGCCAGAA and 3’-
TAAGGTCCCTTAGGCCAACC and the amplification products then directly Sanger sequenced 
in individuals identified in the genome-wide association study as having homozygous risk (n = 
50) or homozygous non-risk (n = 50) rs1042169 and rs141530233 genotypes. A representative 
example of the sequence read-out from each subgroup is shown with the nucleotide sequence and 
corresponding amino acid sequence and position shown below. The polymorphic alleles within 
each haplotype are circled. The sequence analysis confirmed 100% correlation of rs386699872 
CA with the risk and rs386699872 G with the non-risk rs1042169/rs141530233 haplotype.   
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Supplementary Figure 6. Classification And Regression Tree (CART) model for predicting 
risk for GPA/MPA vasculitis. The CART analysis incorporated the disease-associated SNPs 
identified in the initial ANCA-associated vasculitis cohort meta-analysis. The HLA-DQA2 
rs7454108 and PTPN22 rs6679677 and rs2476601 variants that did not substantially improve 
classification of cases and controls were removed from further analyses. Eight other variants 
(HLA-DPA1 rs9277341, HLA-DPB1 rs141530233, HLA-DPB1 rs1042169, PRTN3 rs62132293, 
HLA-DQA1 rs35242582, SERPINA1 rs28929474, HLA-DQB1 rs104902, and HLA-DQA2 
rs39981589) all improved the model fit by at least 3% and were retained to build a CART. The 
three symbols ++, +-, or -- on each split represent minor variant homozygote, heterozygote, or 
homozygote, respectively. Odds ratios (OR) and confidence intervals (bracketed numbers) are 
shown for each node with the effects of specific variants on risk shown for each sequentially 
subclassified patient subset.    
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Table 1. Results of GWAS, replication, and combined association analyses 
GWAS    
    (N=1371 cases. 3258 controls) 
Replication                                                                                                
(N = 615 cases, 1465 controls) 
Combined analysis                        
(N = 1986 cases, 4723 controls) 
      RAF                        RAF         
SNP Locus Position Gene 
Risk 
allele Cases   Controls Pa OR (95% CI)c Cases Controls Pb OR (95% CI) Pc OR (95% CI) 
rs141530233 6p21.32 33048688 HLA-DPB1 A deld 0.86 0.70 5.93 x 10-56 2.76 (2.44 - 3.13) 0.90 0.69 2.45 x 10-39 4.00 (3.23 - 5.00) 1.13 x 10-89 2.99 (2.69 - 3.33) 
rs1042169 6p21.32 33048686 HLA-DPB1 G 0.86 0.70 4.41 x 10-52 2.57 (2.27 - 2.94) 0.90 0.68 1.94 x 10-39 4.00 (3.23 - 5.00) 1.12 x 10-84 2.82 (2.54 - 3.13) 
rs9277341 6p21.32 33039625 HLA-DPA1 T 0.84 0.70 1.62 x 10-40 2.21 (1.96 - 2.50) 0.87 0.66 3.58 x 10-34 3.13 (2.63 - 3.70) 6.09 x 10-71 2.44 (2.21 - 2.69) 
rs35242582 6p21.32 32600057 HLA-DQA1 A 0.82 0.74 3.34 x 10-16 1.61 (1.43 - 1.79) 0.82 0.74 3.59 x 10-8 1.59 (1.35 - 1.89) 6.34 x 10-23 1.60 (1.46 - 1.76) 
rs1049072 6p21.32 32634355 HLA-DQB1 A 0.23 0.17 4.23 x 10-10 1.43 (1.28 - 1.59) 0.21 0.17 1.69 x 10-3 1.30 (1.10 - 1.54) 6.46 x 10-13 1.40 (1.28 - 1.53) 
rs6679677 1p13.2 114303808 PTPN22 A 0.13 0.09 2.40 x 10-8 1.49 (1.30 - 1.72) 0.11 0.09 4.57 x 10-2 1.25 (1.00 - 1.55) 1.88 x 10-8 1.40 (1.25 - 1.57) 





T 0.04 0.02 8.26 x 10-8 2.09 (1.59 - 2.73) 0.04 0.02 6.72 x 10-5 2.18 (1.49 - 3.20) 3.09 x 10-12 2.18 (1.75 - 2.71) 
rs2476601 1p13.2 114377568 PTPN22 (R620W) A 0.13 0.10 3.03 x 10-7 1.45 (1.26 - 1.66) 0.11 0.09 5.38 x 10-2 1.24 (1.00 - 1.53) 1.86 x 10-7 1.36 (1.21 - 1.53) 
 
Legend: CI, confidence interval; A del, adenosine deletion; OR, odds ratio; RAF, risk allele frequency. 
a




Pvalues for the combined GWAS and replication datasets calculated using the Cochran-Mantel-Haenszel method of 
combining allele frequency counts. 
d 
rs141530233 is an insertion/deletion (indel) polymorphism, the risk genotype lacking and the non-risk genotype containing an adenosine residue at 
nucleotide position 33048688. 
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Table 2. Effects of clinical and serologic status on the MHC and non-MHC associations with ANCA-associated vasculitis. 
A. Subgroup comparisons 
      
Overall analysis of 
combined cohort 
 (N = 1986 cases,  
4723 controls) 
Clinical syndrome ANCA specificity 
GPA (N = 1556) vs 
Controls (N = 4723) 
MPA (N = 236) vs 
Controls (N = 4723) 
GPA (N = 1556) vs 
MPA (N = 236) 
PR3/cANCA  
(N = 1361) vs 
Controls (N = 4723) 
MPO/pANCA  
(N = 378) vs 
Controls (N = 4723) 
PR3/cANCA  
(N = 1361) vs 
MPO/pANCA  
(N = 378) 
SNP Locus Gene 
Risk 
allele P OR P OR P OR P OR P OR P OR P OR 
rs141530233 6p21.32 HLA-DPB1 A del 1.13 x 10-89 2.99 3.80 x 10-93 3.82 9.45 x 10-5 1.58 1.45 x 10-9 2.04 1.33 x 10-106 6.19 1.50 x 10-2 1.24 3.53 x 10-32 3.93 
rs1042169 6p21.32 HLA-DPB1 G 1.12 x 10-84 2.82 1.09 x 10-90 3.66 2.22 x 10-3 1.40 9.50 x 10-12 2.18 6.53 x 10-106 6.09 1.27 x 10-1 1.14 3.44 x 10-36 4.27 
rs9277341 6p21.32 HLA-DPA1 T 6.09 x 10-71 2.44 2.78 x 10-73 2.86 9.40 x 10-4 1.45 4.96 x 10-7 1.79 4.52 x 10-84 3.69 3.61 x 10-3 1.29 4.55 x 10-20 2.61 
rs35242582 6p21.32 HLA-DQA1 A 6.34 x 10-23 1.60 1.60 x 10-20 1.63 8.91 x 10-3 1.36 1.36 x 10-1 1.20 5.78 x 10-18 1.62 2.34 x 10-7 1.68 7.67 x 10-1 1.03 
rs1049072 6p21.32 HLA-DQB1 A 6.46 x 10-13 1.40 1.40 x 10-7 1.31 4.16 x 10-9 1.89 2.99 x 10-3 1.39 3.82 x 10-3 1.17 2.13 x 10-24 2.37 7.53 x 10-13 1.94 
rs6679677 1p13.2 PTPN22 A 1.88 x 10-8 1.40 2.38 x 10-7 1.40 8.96 x 10-4 1.58 5.48 x 10-1 1.09 7.89 x 10-6 1.36 8.83 x 10-7 1.71 1.08 x 10-1 1.21 
rs62132293 19p13.3 PRTN3 G 8.60 x 10-11 1.29 7.06 x 10-11 1.32 1.12 x 10-1 1.17 2.70 x 10-1 1.12 3.59 x 10-13 1.39 5.66 x 10-1 1.05 3.22 x 10-5 1.45 




A 1.86 x 10-7 1.36 1.77 x 10-6 1.36 1.31 x 10-3 1.56 4.95 x 10-1 1.10 3.19 x 10-5 1.33 5.85 x 10-6 1.64 1.40 x 10-1 1.19 
 
Legend: ANCA = Anti-neutrophil cytoplasmic autoantibody; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; cANCA 
= cytoplasmic ANCA; pANCA = perinuclar ANCA; MPO = myeloperoxidase; PR3 = proteinase 3; 
N = numbers of subjects; OR = odds ratio; P = Eigenstrat P value. 
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Table 2. Effects of clinical and serologic status on the MHC and non-MHC associations with ANCA-associated vasculitis 
B. GWAS, replication and combined analysis of MPO/pANCA subgroup 
          GWAS Replication Combined      
Analysis in combined 
PR3/cANCA patients 
N = 324 MPO/pANCA, 3258 controls N = 54 MPO/pANCA, 1465 controls 
N = 378 MPO/pANCA,           
4723 controls 
 N = 1361 PR3/cANCA,         
4723 controls 
RAF     RAF         
SNP Locus Position Gene 
Risk 
allele Cases Controls P OR (95% CI) Cases Controls P OR (95% CI) P OR (95% CI) P OR (95% CI) 
rs3998159 6p21.32 32682019 HLA-DQA2 C 0.23 0.10 3.47 x 10-19 2.61 (2.12 - 3.22) 0.25 0.09 7.11 x 10-7 3.25 (2.04 - 5.18) 5.24 x 10-25 2.72 (2.24 - 3.22) 5.18 x 10-1 1.05 (0.91 - 1.20) 
rs7454108 6p21.32 32681483 HLA-DQA2 C 0.23 0.10 3.90 x 10-19 2.61 (2.12 - 3.23) 0.25 0.09 4.78 x 10-7 3.34 (2.09 - 5.33) 5.03 x 10-25 2.73 (2.25 - 3.24) 5.48 x 10-1 1.04 (0.90 - 1.20) 
rs1049072 6p21.32 32634355 HLA-DQB1 A 0.32 0.17 1.63 x 10-18 2.27 (1.89 - 2.72) 0.35 0.17 3.16 x 10-6 2.60 (1.74 -3.88) 2.13 x 10-24 2.37 (2.01 - 2.78) 3.82 x 10-3 1.17 (1.06 - 1.31) 
 
Legend: ANCA = Anti-neutrophil cytoplasmic autoantibody; MPO = myeloperoxidase; pANCA = perinuclear ANCA; GWAS = genome-wide association 
screen; OR = odds ratios; RAF = risk allele frequency; PR3 = proteinase 3; P = Eigenstrat P values. 
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Table 3. Population-Attributable Fraction for Disease-Associated SNPs at the MHC and non-MHC loci. 
AAV GPA MPA PR3/cANCA MPO/pANCA 
Gene SNP RAF OR PAF   OR PAF   OR PAF   OR PAF   OR PAF 
HLA-DPB1  rs141530233 0.70 2.36 0.49 3.01 0.58 1.64 0.31 3.98 0.68 1.01 0.00 
HLA-DPA1  rs9277341 0.70 1.62 0.30 1.81 0.36 1.26 0.00 1.84 0.37 1.03 0.00 
HLA-DQA1  rs35242582 0.74 1.39 0.22 1.46 0.26 1.06 0.00 1.27 0.17 1.02 0.00 
HLA-DQB1  rs1049072 0.17 1.33 0.05 1.19 0.00 1.91 0.13 1.16 0.00 2.64 0.22 
PRTN3  rs62132293 0.31 1.27 0.08 1.30 0.09 1.18 0.00 1.59 0.16 1.10 0.00 
SERPINA1  rs28929474 0.02 2.13 0.02 2.43 0.02 1.98 0.00 3.64 0.04 2.98 0.00 
PTPN22 (R620W)  rs2476601 0.10 1.45 0.04 1.47 0.04 1.62 0.06 1.71 0.06 2.18 0.10 
Combined       0.77     0.83     0.43     0.87     0.30 
 
Legend: Population-attributable fraction (PAF) were calculated from the combined overall ANCA-associated vasculitis (AAV) and from 
clinically and serologically defined subgroups. GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; PR3 = proteinase 3; 
MPO = myeloperoxidase; RAF = risk allele frequency in healthy controls; OR = odds ratio. 
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Figure 1. AAV-associated rs62132293 variant is associated with increases in PRTN3 expression.  
 
245x136mm (300 x 300 DPI)  
 
 
Page 35 of 69
John Wiley & Sons
Arthritis & Rheumatology













Figure 2. rs1042169 alleles are associated with differential HLA-DPB1 expression and T cell responses.  
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Supplementary Table 1. Sequences of primer pairs used in quantitative PCR analyses.
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Oxy271 control peptide 271EKKYFAATQFEPLAARL287
Supplementary Table 2. Sequences of 20mer peptides used to evaluate T cell responses.
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Discovery1 Genotyped Post QC GPA MPA Kidney Lung3 PR3-ANCA MPO-ANCA
Cases
WGGER 438 377 360 (95.5) 0 208 (55.2) 203 (53.9) 298 (79.1) 25 (0.07)
VCRC 779 668 564 (84.4) 76 (11.4) 405 (60.6) 481 (72.0) 446 (66.8) 152 (22.8)
UNC Kidney Center 378 326 91 (27.9) 130 (39.9) 218 (66.9) 144 (44.2) 138 (42.3) 147 (45.1)
Total 1615 1371 1015 (74.0) 206 (15) 831 (60.6) 828 (60.4) 882 (64.3) 324 (23.6)




GERA historic controls 3121 3074
Total 3323 3258




Toronto 505 501 459 (91.6) 3 (0.6) 265 (52.9) 307 (61.3) 413 (82.4) 20 (4.0)
VCRC 114 114 82 (71.9) 27 (23.7) 75 (65.8) 65 (57.0) 66 (57.9) 34 (29.8)
Total 619 615 541 (88.0) 30 (4.9) 340 (55.3) 372 (60.5) 479 (77.9) 54 (8.8)




Age at recruitment  (Mean ± SD) 33 ± 16
Female (%) 74
Overall Cases 1986 1556 236 1171 1200 1361 378
Controls 4723
Legend: ANCA = anti-neutrophil cytoplasmic autoantibody; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; GERA = Genetic Epidemiology Research on Aging
PR3 = proteinase-3; MPO = myeloperoxidase; VCRC = Vasculitis Clinical Research Consortium; WGGER = Wegener's Granulomatosis Genetic Repository; UNC = University of North Carolina
Post-QC refers to subjects in whom genotyping passed all quality control measures and principal component analysis.
1 The WGGER and VCRC cases and WGGER controls included in the discovery GWAS were also included in a prior replication association analysis specifically testing association of 5 candidate loci with GPA (1)
2 The “Toronto” cases (505) and 380 of the “Toronto” controls included in the replication analysis were previously studied in a prior GWAS on GPA conducted by our group (1)
3 Diagnosis of lung involvement was based on reported pleuritis/pleural effusion, nodules or cavities, endobronchial involvement, alveolar hemorrhage or other pulmonary infiltrate
4 ANCA specificity defined by PR3 or MPO-ANCA specificity and/or by non-antigen specific immunofluorescence ANCA assays
Supplementary Table 3. Summary of patient demographics, clinical data and quality controls outcomes by cohort
Clinical features of cases
Diagnosis (%) Organ Involvement (%)Subject numbers
ANCA specificity of cases4    
Number (%)
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SNP Chromosome Position Gene Risk allele P  value OR
rs141530233 6p21.32 33048688 HLA-DPB1 - 5.93E-56 2.76
rs1042169 6p21.32 33048686 HLA-DPB1 G 4.41E-52 2.57
rs9277554 6p21.32 33055538 HLA-DPB1 C 4.97E-48 2.52
rs1071597 6p21.32 33052986 HLA-DPB1 T 1.08E-47 2.49
rs9277410 6p21.32 33051640 HLA-DPB1 G 1.90E-47 2.48
rs9277424 6p21.32 33051865 HLA-DPB1 A 3.11E-47 2.48
rs9277546 6p21.32 33055346 HLA-DPB1 T 5.72E-47 2.47
rs9277514 6p21.32 33054235 HLA-DPB1 T 5.80E-47 2.47
rs9277498 6p21.32 33054141 HLA-DPB1 T 6.33E-47 2.46
rs9277471 6p21.32 33053682 HLA-DPB1 G 7.62E-47 2.46
rs2064476 6p21.32 33073322 HLA-DPB1 A 9.30E-47 2.46
rs1042335 6p21.32 33052958 HLA-DPB1 C 9.66E-46 2.44
rs1431403 6p21.32 33047031 HLA-DPB1 T 1.38E-43 2.41
rs2144014 6p21.32 33065813 HLA-DPB1 G 2.34E-41 2.47
rs9277341 6p21.32 33039625 HLA-DPA1 T 1.62E-40 2.21
rs3117223 6p21.32 33060064 HLA-DPB1 G 7.69E-40 2.42
rs2395314 6p21.32 33062673 HLA-DPB1 G 1.04E-39 2.42
rs3128917 6p21.32 33059996 HLA-DPB1 T 1.26E-39 2.42
rs3128921 6p21.32 33070749 HLA-DPB1 C 2.11E-39 2.44
rs1042153 6p21.32 33048663 HLA-DPB1 G 4.31E-39 2.67
rs9277535 6p21.32 33054861 HLA-DPB1 A 4.74E-39 2.43
rs3128927 6p21.32 33074288 HLA-DPB1 C 6.44E-39 2.30
rs9277464 6p21.32 33053352 HLA-DPB1 C 7.11E-39 2.42
rs3135024 6p21.32 33047466 HLA-DPB1 T 7.44E-39 2.45
rs3130190 6p21.32 33061690 HLA-DPB1 T 1.04E-38 2.39
rs9277489 6p21.32 33053942 HLA-DPB1 T 1.42E-38 2.40
rs3117231 6p21.32 33074908 HLA-DPB1 A 1.23E-37 2.37
rs1042151 6p21.32 33048661 HLA-DPB1 A 2.85E-35 2.75
rs1126513 6p21.32 33048467 HLA-DPB1 G 9.27E-34 2.35
rs2179920 6p21.32 33058874 HLA-DPB1 C 5.71E-32 2.30
rs9277567 6p21.32 33057013 HLA-DPB1 A 1.48E-31 2.36
rs2064474 6p21.32 33073463 HLA-DPB1 G 1.53E-31 2.24
rs2064478 6p21.32 33072266 HLA-DPB1 C 1.63E-31 2.27
rs3117230 6p21.32 33075635 HLA-DPB1 A 2.12E-31 2.26
rs1042434 6p21.32 33036505 HLA-DPA1 G 3.13E-31 2.62
rs3077 6p21.32 33033022 HLA-DPA1 A 9.84E-31 2.60
Affx-28512827 6p21.32 33037424 HLA-DPA1 T 2.15E-30 2.59
rs2308911 6p21.32 33037580 HLA-DPA1 T 2.48E-30 2.59
Affx-28512796 6p21.32 33036853 HLA-DPA1 A 4.25E-30 2.57
rs17214533 6p21.32 33032272 HLA-DOA C 7.68E-30 2.57
rs10214910 6p21.32 33037675 HLA-DPA1 C 7.88E-30 2.56
Supplementary Table 4. Results of genome-wide association analysis for ANCA-
associated vasculitis.
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SNP Chromosome Position Gene Risk allele P  value OR
rs1431399 6p21.32 33041034 HLA-DPA1 A 1.37E-29 2.54
rs910320 6p21.32 33075443 HLA-DPB1 C 1.27E-28 2.18
rs1126769 6p21.32 33036435 HLA-DPA1 T 1.04E-27 2.49
rs2071352 6p21.32 33044188 HLA-DPB1 T 3.22E-27 3.01
rs439205 6p21.32 33173842 HSD17B8 G 6.32E-27 2.00
rs1042190 6p21.32 33036999 HLA-DPA1 T 7.03E-27 2.53
rs2071025 6p21.32 33143756 COL11A2 A 2.02E-26 1.99
rs2076310 6p21.32 33166034 RXRB A 7.10E-26 1.96
rs2281389 6p21.32 33059796 HLA-DPB1 A 1.02E-24 2.24
rs2858458 6p21.32 33003065 HLA-DOA T 6.23E-24 1.85
rs3097671 6p21.32 33047612 HLA-DPB1 G 8.27E-24 2.24
rs421446 6p21.32 33174783 HSD17B8 A 2.80E-23 1.77
rs213209 6p21.32 33176958 RING1 C 3.23E-23 1.79
rs1126543 6p21.32 33037419 HLA-DPA1 G 1.14E-22 2.16
rs987870 6p21.32 33042880 HLA-DPA1 A 3.38E-22 2.37
rs9277935 6p21.32 33160425 COL11A2 G 1.13E-21 1.91
rs3117016 6p21.32 33095516 HLA-DPB2 G 3.57E-20 1.58
rs986521 6p21.32 33136145 COL11A2 G 2.04E-18 1.56
rs439121 6p21.32 33192867 RING1 A 1.12E-16 1.64
rs213212 6p21.32 33185918 RING1 C 1.30E-16 1.51
rs213194 6p21.32 33195604 RING1 A 1.80E-16 1.50
rs213213 6p21.32 33183730 RING1 T 2.54E-16 1.48
rs3130161 6p21.32 33125858 COL11A2 A 2.65E-16 2.04
rs2855442 6p21.32 33137403 COL11A2 C 3.27E-16 1.49
rs35242582 6p21.32 32600057 HLA-DQA1 A 3.34E-16 1.61
rs2855425 6p21.32 33144373 COL11A2 G 3.92E-16 1.49
rs3116994 6p21.32 33098797 COL11A2 G 7.30E-16 1.46
rs6531 6p21.32 33163451 RXRB G 9.30E-16 1.48
rs2744512 6p21.32 33141920 COL11A2 G 1.13E-15 1.50
rs3129270 6p21.32 33097423 COL11A2 C 1.23E-13 1.96
rs7772134 6p21.32 33049726 HLA-DPB1 G 1.90E-13 2.17
rs3129207 6p21.32 33125312 COL11A2 G 2.47E-13 1.40
rs2855437 6p21.32 33138955 COL11A2 G 2.83E-13 1.43
rs3117008 6p21.32 33096274 HLA-DPB2 G 3.20E-13 1.40
rs1883414 6p21.32 33086448 HLA-DPB2 G 5.43E-13 1.46
rs9277946 6p21.32 33194717 RING1 C 5.62E-13 1.78
rs3129294 6p21.32 33084671 HLA-DPB2 A 6.57E-13 1.43
rs2855459 6p21.32 33154656 COL11A2 G 8.59E-13 1.77
rs3129274 6p21.32 33094869 HLA-DPB2 C 1.27E-12 1.41
rs3129267 6p21.32 33098896 COL11A2 C 1.37E-12 1.41
rs660895 6p21.32 32577380 HLA-DRB1 G 1.70E-12 1.47
rs28584179 6p21.32 32626119 HLA-DQA1 C 1.78E-12 1.94
rs116518618 6p21.32 32594998 HLA-DRB1 C 1.80E-12 1.94
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SNP Chromosome Position Gene Risk allele P  value OR
rs9271897 6p21.32 32595954 HLA-DRB1 G 3.68E-12 1.38
rs3116999 6p21.32 33097166 COL11A2 G 1.22E-11 1.61
rs1882 6p21.33 31382911 MICA A 1.94E-11 1.38
rs3097669 6p21.32 33023792 HLA-DOA A 2.94E-11 1.47
rs3130176 6p21.32 33017457 HLA-DOA A 3.19E-11 1.36
rs9271824 6p21.32 32594916 HLA-DRB1 A 3.47E-11 1.36
rs3134926 6p21.32 32200147 NOTCH4 C 4.60E-11 1.42
rs2294479 6p21.32 33098389 COL11A2 G 5.44E-11 1.40
Affx-52341735 6p21.32 33138955 COL11A2 G 2.19E-10 1.36
rs2254287 6p21.32 33143948 COL11A2 C 2.57E-10 1.36
rs726599 6p21.32 33121678 COL11A2 C 3.85E-10 1.35
rs1049072 6p21.32 32634355 HLA-DQB1 A 4.23E-10 1.43
rs2855448 6p21.32 33136575 COL11A2 C 1.05E-09 1.34
rs9272105 6p21.32 32599999 HLA-DRB1 G 1.08E-09 1.32
rs2257126 6p21.32 33131734 COL11A2 A 1.16E-09 1.34
rs2596530 6p21.33 31387373 MICA G 1.37E-09 1.34
rs9273088 6p21.32 32612488 HLA-DQA1 C 1.41E-09 1.33
rs2395175 6p21.32 32405026 HLA-DRA A 2.08E-09 1.42
rs9296068 6p21.32 32988695 HLA-DOA T 2.55E-09 1.35
rs1130399 6p21.32 32629755 HLA-DQB1 A 2.94E-09 1.40
rs2256183 6p21.33 31380529 MICA A 3.05E-09 1.33
rs1810472 6p21.32 33083121 HLA-DPB2 T 3.37E-09 1.37
rs213210 6p21.32 33175824 RING1 A 4.30E-09 1.99
rs9272116 6p21.32 32600404 HLA-DQA1 T 6.01E-09 1.31
rs9368758 6p21.32 33138021 COL11A2 G 6.60E-09 1.98
rs75549913 6p21.33 31390139 MICA - 6.65E-09 1.33
rs9273215 6p21.32 32613712 HLA-DQA1 G 6.75E-09 1.31
rs438999 6p21.33 31928306 SKIV2L A 7.46E-09 1.73
rs541862 6p21.33 31916951 CFB T 7.90E-09 1.73
rs763469 6p21.32 33004387 HLA-DOA A 8.02E-09 1.41
rs9274552 6p21.32 32634838 HLA-DQB1 C 9.40E-09 1.31
rs6936620 6p21.32 32984451 HLA-DOA A 1.18E-08 1.31
rs3096702 6p21.32 32192331 NOTCH4 A 1.38E-08 1.31
rs3130604 6p21.32 32985052 HLA-DOA G 1.76E-08 1.40
rs2068204 6p21.32 33058718 HLA-DPB1 G 1.87E-08 2.82
rs1063355 6p21.32 32627714 HLA-DQB1 G 1.89E-08 1.30
rs17612576 6p21.32 32615458 HLA-DQA1 A 1.92E-08 1.30
rs382259 6p21.32 32209027 NOTCH4 T 2.07E-08 1.36
rs2070600 6p21.32 32151443 AGER T 2.10E-08 1.71
rs199556640 6p21.32 32609299 HLA-DQA1 - 2.27E-08 1.30
rs6679677 1p13.2 114303808 PTPN22 A 2.40E-08 1.49
rs3129304 6p21.32 32973743 HLA-DOA C 2.66E-08 1.39
rs429608 6p21.33 31930462 SKIV2L G 2.98E-08 1.49
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SNP Chromosome Position Gene Risk allele P  value OR
rs17843619 6p21.32 32620775 HLA-DQA1 A 3.47E-08 1.29
rs3132454 6p21.33 31489644 MCCD1 A 3.93E-08 1.32
rs9272346 6p21.32 32604372 HLA-DQA1 A 4.89E-08 1.29
rs62132293 19p13.3 838178 PRTN3 G 5.55E-08 1.30
rs9468925 6p21.33 31258837 HLA-C G 6.28E-08 1.30
rs429916 6p21.32 32978587 HLA-DOA C 7.41E-08 1.79
rs6910071 6p21.32 32282854 C6orf10 G 7.87E-08 1.35
rs3793127 6p21.32 32371915 BTNL2 T 7.96E-08 1.33
rs28929474 14q32.13 94844947 SERPINA1 T 8.26E-08 2.09
rs2844514 6p21.33 31380340 MICA C 8.29E-08 1.29
rs1129808 6p21.32 32609312 HLA-DQA1 C 8.40E-08 1.28
rs389512 6p21.33 31947594 STK19 G 8.57E-08 1.52
rs2857107 6p21.32 32785515 HLA-DOB C 8.63E-08 1.55
rs1894411 6p21.32 32792973 TAP2 T 9.43E-08 1.55
rs34892006 6p22.1 29012712 OR2W1 C 9.47E-08 13.46
rs387608 6p21.33 31941557 STK19 G 1.01E-07 1.52
Affx-28465058 6p21.33 31936679 SKIV2L C 1.01E-07 1.52
rs2844513 6p21.33 31388214 MICA G 1.06E-07 1.29
Affx-28513472 6p21.32 33053577 HLA-DPB1 G 1.08E-07 2.16
rs206762 6p21.32 32970450 BRD2 G 1.15E-07 1.28
rs9263873 6p21.33 31170713 HCG27 T 1.21E-07 1.29
rs2517424 6p21.33 30949996 MUC21 T 1.30E-07 1.48
rs2524040 6p21.33 31257625 HLA-C T 1.36E-07 1.29
rs805284 6p21.33 31682029 LY6G6D A 1.38E-07 1.69
rs1143260 6p21.32 32359227 HCG23 A 1.46E-07 1.52
rs3873386 6p21.33 31273745 HLA-C T 1.59E-07 1.29
rs9380343 6p21.32 33079166 HLA-DPB1 C 1.66E-07 2.51
rs2395163 6p21.32 32387809 HLA-DRA C 1.79E-07 1.32
rs17843606 6p21.32 32620399 HLA-DQA1 T 1.84E-07 1.28
rs444921 6p21.33 31932177 SKIV2L C 1.88E-07 1.51
rs213226 6p21.32 33209310 RING1 A 2.04E-07 1.27
rs3130257 6p21.32 33256471 WDR46 T 2.16E-07 1.42
rs2857605 6p21.33 31524851 NFKBIL1 C 2.63E-07 1.32
rs2476601 1p13.2 114377568 PTPN22 (R620W) A 3.03E-07 1.45
rs211449 6p21.32 33333916 DAXX G 3.05E-07 1.29
rs4713447 6p21.33 31162963 PSORS1C3 A 3.27E-07 1.28
rs2228396 6p21.32 32797809 TAP2 T 3.36E-07 1.48
rs3097648 6p21.32 32990970 HLA-DOA A 3.67E-07 1.50
rs34252386 6p21.32 32546912 HLA-DRB1 G 4.03E-07 1.28
rs6457374 6p21.33 31272261 HLA-C C 4.24E-07 1.30
rs9277348 6p21.32 33048538 HLA-DPB1 T 4.37E-07 3.07
rs67523850 6p21.32 33054014 HLA-DPB1 A 5.48E-07 2.12
rs1130368 6p21.32 32632818 HLA-DQB1 T 5.71E-07 1.39
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rs511294 6p21.33 31888869 C2 T 5.86E-07 1.75
Affx-28512853 6p21.32 33037640 HLA-DPA1 C 6.46E-07 2.59
rs3132680 6p22.1 30073195 TRIM31 A 6.48E-07 1.28
rs3094672 6p21.33 30993377 MUC22 T 6.57E-07 1.29
rs6928399 6p21.33 31195218 HLA-C C 6.71E-07 1.29
rs9348906 6p21.32 33080360 HLA-DPB2 T 7.08E-07 2.89
rs6928482 6p21.32 32626249 HLA-DQA1 C 7.11E-07 1.26
rs605203 6p21.33 31847012 EHMT2 C 7.22E-07 1.27
rs486416 6p21.33 31856070 EHMT2 G 7.96E-07 1.27
rs1062481 6p21.32 33037611 HLA-DPA1 C 9.54E-07 2.59
rs6899309 6p21.32 32915823 HLA-DMB T 1.01E-06 1.86
rs2247056 6p21.33 31265490 HLA-C T 1.01E-06 1.29
rs659445 6p21.33 31864304 EHMT2 G 1.17E-06 1.26
rs9380345 6p21.32 33080359 HLA-DPB2 C 1.18E-06 2.79
rs35445101 6p21.32 32546879 HLA-DRB1 G 1.20E-06 1.26
rs2240070 6p22.1 30071110 TRIM31 T 1.21E-06 1.27
rs9267873 6p21.32 32199352 NOTCH4 C 1.26E-06 1.26
rs440454 6p21.33 31927342 SKIV2L A 1.26E-06 1.27
rs423209 6p21.32 32983474 HLA-DOA G 1.27E-06 2.26
rs638383 6p21.33 31908224 C2 C 1.30E-06 2.02
rs213220 6p21.32 33202640 RING1 C 1.30E-06 1.25
rs7264431 20p13 1716975 SIRPG C 1.36E-06 1.44
rs2853931 6p21.33 31255007 HLA-C C 1.37E-06 1.25
rs3905495 6p21.33 31265539 HLA-C G 1.38E-06 1.27
rs4642516 6p21.32 32657543 HLA-DQA2 T 1.39E-06 1.25
Affx-52368679 6p21.32 32632863 HLA-DQB1 CGGT 1.41E-06 1.26
rs3134996 6p21.32 32636866 HLA-DQB1 T 1.43E-06 1.26
rs7755364 6p21.33 30981715 MUC22 G 1.50E-06 1.43
rs3998159 6p21.32 32682019 HLA-DQA2 C 1.55E-06 1.40
rs7454108 6p21.32 32681483 HLA-DQA2 C 1.56E-06 1.40
rs28366130 6p21.33 31363805 MICA A 1.61E-06 1.28
rs166325 6p22.1 29993196 ZNRD1-AS1 G 1.64E-06 1.67
rs1269851 6p21.33 32092207 ATF6B T 1.77E-06 1.98
rs423639 6p21.32 32987774 HLA-DOA C 1.82E-06 1.62
rs176248 6p21.32 32965942 BRD2 G 1.85E-06 1.30
rs9366814 6p21.32 33080799 HLA-DPB2 T 1.88E-06 2.57
Affx-37072023 6p21.32 32612430 HLA-DQA1 C 1.91E-06 1.25
rs28366302 6p21.32 32560934 HLA-DRB1 C 1.92E-06 1.26
rs41267649 6p21.32 33384473 CUTA T 2.03E-06 1.91
rs419788 6p21.33 31928799 SKIV2L T 2.07E-06 1.27
rs365053 6p21.32 32195988 NOTCH4 T 2.14E-06 1.30
rs204890 6p21.33 32085598 ATF6B C 2.16E-06 2.07
rs2844529 6p21.33 31353593 MICA G 2.52E-06 1.27
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rs3130609 6p21.32 32989521 HLA-DOA C 2.54E-06 2.32
rs3873444 6p21.32 32682724 HLA-DQA2 C 2.66E-06 1.55
rs2523467 6p21.33 31362930 MICA C 2.77E-06 1.27
rs2523554 6p21.33 31331829 MICA C 2.85E-06 1.25
rs1634717 6p21.33 30972589 MUC22 G 2.89E-06 1.24
rs4668338 2q31.1 171733225 GAD1 C 3.04E-06 4.70
rs241438 6p21.32 32797620 TAP2 C 3.19E-06 1.26
rs535586 6p21.33 31860337 EHMT2 T 3.24E-06 1.25
rs3819721 6p21.32 32804798 TAP2 A 3.34E-06 1.27
rs437179 6p21.33 31929014 SKIV2L A 3.43E-06 1.26
rs115771946 6p22.1 29837127 HLA-G T 3.70E-06 1.63
rs2844795 6p22.1 30073847 TRIM31 C 4.02E-06 1.24
rs2853933 6p21.33 31254088 HLA-C T 4.08E-06 1.24
rs2596542 6p21.33 31366595 MICA C 4.11E-06 1.26
rs2523473 6p21.33 31361897 MICA A 4.28E-06 1.26
Affx-28507878 6p21.32 32823948 PSMB9 G 4.50E-06 2.59
rs448733 6p21.32 33003687 HLA-DOA C 4.66E-06 1.83
rs9274697 6p21.32 32637016 HLA-DQB1 G 4.77E-06 1.23
rs2395185 6p21.32 32433167 HLA-DRB5 T 5.07E-06 1.25
rs34182778 6p21.33 31084943 CDSN - 5.27E-06 1.29
rs2524163 6p21.33 31259579 HLA-C C 5.81E-06 1.24
rs259937 6p22.1 30007493 ZNRD1-AS1 T 5.97E-06 1.62
rs4412248 6p21.32 33072415 HLA-DPB1 C 6.08E-06 3.25
rs630379 6p21.33 31922254 NELFE A 6.19E-06 1.25
rs7041467 9q21.32 85865570 FRMD3 G 6.26E-06 5.77
rs389883 6p21.33 31947460 STK19 G 6.48E-06 1.25
rs2524089 6p21.33 31266522 HLA-C G 6.60E-06 1.23
rs12662501 6p21.33 31190850 HLA-C C 6.62E-06 1.37
rs9268923 6p21.32 32432835 HLA-DRB5 T 6.68E-06 1.24
rs146599962 18q21.31 55398906 ATP8B1 G 6.69E-06 16.56
rs5024432 6p21.32 32684468 HLA-DQA2 C 6.91E-06 1.44
rs498422 6p21.32 32286761 C6orf10 T 6.97E-06 1.61
rs150018949 1p34.2 40981245 EXO5 G 7.07E-06 1.82
rs204894 6p21.33 32093922 ATF6B G 7.43E-06 1.80
rs9275184 6p21.32 32654714 HLA-DQA2 C 7.81E-06 1.37
rs4726308 7q36.2 153290520 DPP6 T 7.86E-06 1.24
rs213199 6p21.32 33235755 VPS52 G 8.24E-06 1.24
rs3117034 6p21.32 33087358 HLA-DPB2 T 8.42E-06 1.23
rs411337 6p21.33 32077380 ATF6B C 8.79E-06 1.55
rs3093983 6p21.33 31496925 MCCD1 G 8.90E-06 1.28
rs10484561 6p21.32 32665420 HLA-DQA2 T 8.91E-06 1.41
rs1619376 6p21.33 30983326 MUC22 A 9.04E-06 1.27
rs6457144 6p22.1 30063368 TRIM31 T 9.05E-06 1.23
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rs202081894 11p15.5 824567 PNPLA2 C 9.12E-06 4.40
rs2071285 6p21.32 32180431 NOTCH4 T 9.24E-06 1.47
rs2854050 6p21.32 32185605 NOTCH4 A 9.63E-06 1.47
rs2243868 6p21.33 31261276 HLA-C A 1.04E-05 1.23
rs1241983 18p11.31 6875693 ARHGAP28 A 1.04E-05 1.22
rs6937034 6p21.32 33079766 HLA-DPB1 A 1.06E-05 2.30
rs6457702 6p21.32 32988049 HLA-DOA T 1.10E-05 1.23
rs2517421 6p21.33 30951209 MUC21 C 1.17E-05 1.36
rs2249168 6p21.33 30958254 MUC22 C 1.19E-05 1.36
rs3131631 6p21.33 31484683 MCCD1 G 1.19E-05 1.25
rs204888 6p21.33 32089142 ATF6B G 1.20E-05 1.54
rs2116263 6p21.32 33025493 HLA-DOA G 1.28E-05 2.82
rs213204 6p21.32 33241076 RPS18 C 1.32E-05 1.24
rs2523915 6p21.33 30973358 MUC22 T 1.34E-05 1.36
rs56291618 7p22.3 164282 FAM20C A 1.39E-05 1.87
rs2853939 6p21.33 31250642 HLA-C T 1.41E-05 1.22
rs213202 6p21.32 33232055 VPS52 G 1.44E-05 1.24
rs2517409 6p21.33 30964393 MUC22 T 1.48E-05 1.36
rs59726684 8p21.2 24775457 NEFM C 1.48E-05 1.96
rs204879 6p21.33 32043157 TNXB T 1.49E-05 2.03
rs204996 6p21.32 32149883 AGER C 1.54E-05 1.75
rs9391630 6p22.1 29722515 HCG4 G 1.58E-05 1.26
rs61815115 1q21.3 151783324 RORC G 1.58E-05 1.40
rs2229784 6p21.32 33136310 COL11A2 G 1.59E-05 2.24
rs2341320 2q37.1 232740108 COPS7B T 1.62E-05 1.22
rs67529500 6p21.32 32504757 HLA-DRB5 G 1.64E-05 1.22
rs3135195 6p21.32 32999330 HLA-DOA T 1.65E-05 2.25
rs3132682 6p22.1 30044388 TRIM31 G 1.76E-05 1.22
rs6909253 6p22.1 30055643 TRIM31 G 1.96E-05 1.22
rs1042149 6p21.33 31082960 CDSN A 1.98E-05 1.22
rs9271709 6p21.32 32593392 HLA-DRB1 G 1.99E-05 1.24
rs2524074 6p21.33 31244021 HLA-C G 2.01E-05 1.23
rs77637983 6p21.32 32549452 HLA-DRB1 C 2.07E-05 1.22
rs700726 8q12.1 60931328 CA8 T 2.08E-05 1.22
rs2844682 6p21.33 30946148 MUC21 G 2.14E-05 1.35
rs106287 6p21.33 31935750 SKIV2L G 2.14E-05 2.01
rs2523685 6p21.33 31426256 MICA G 2.24E-05 1.27
rs2523921 6p21.33 30975090 MUC22 T 2.28E-05 1.35
rs142478577 4p16.3 2994002 GRK4 C 2.41E-05 15.67
rs4713422 6p21.33 30999902 MUC22 G 2.44E-05 1.23
rs2255625 6p21.33 30940705 MUC21 A 2.56E-05 1.35
rs3104401 6p21.32 32687358 HLA-DQA2 A 2.62E-05 1.34
rs169494 6p21.33 32097876 FKBPL G 2.66E-05 1.51
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rs62399430 6p21.33 30993866 MUC22 A 2.66E-05 1.36
rs211450 6p21.32 33333446 DAXX C 2.71E-05 1.23
rs2517439 6p21.33 30942929 MUC21 G 2.85E-05 1.35
rs653667 1p36.22 12251808 TNFRSF1B T 2.85E-05 1.23
rs3094212 6p21.33 31085770 CDSN G 2.90E-05 1.21
rs204885 6p21.33 32029929 TNXB C 3.00E-05 1.94
rs241436 6p21.32 32797876 TAP2 A 3.11E-05 1.22
rs261945 6p22.1 30272417 HCG18 C 3.12E-05 1.22
rs2596501 6p21.33 31321211 HLA-C C 3.12E-05 1.21
rs9261485 6p22.1 30108751 TRIM40 A 3.14E-05 1.25
rs213203 6p21.32 33238404 VPS52 A 3.15E-05 1.21
rs5027459 6p21.32 32719028 HLA-DQB2 G 3.25E-05 1.24
rs73727981 6p21.32 32511791 HLA-DRB5 A 3.38E-05 1.21
rs3132554 6p21.33 31084163 CDSN A 3.42E-05 1.21
rs4713438 6p21.33 31146846 PSORS1C3 G 3.43E-05 1.30
rs10947121 6p21.33 30999997 MUC22 T 3.48E-05 1.23
rs2516472 6p21.33 31394700 MICA A 3.63E-05 1.51
rs15574 6p21.33 31686497 LY6G6C G 3.67E-05 1.28
rs2844463 6p21.33 31615167 BAG6 G 3.80E-05 1.35
rs4807840 19p13.3 6156483 ACSBG2 C 3.81E-05 1.23
rs34411532 6p21.32 32592294 HLA-DRB1 G 3.94E-05 1.31
rs1562284 13q12.12 25297674 ATP12A T 3.98E-05 1.36
rs3129264 6p21.32 33101602 COL11A2 A 4.02E-05 1.26
rs2239707 6p21.33 31525319 NFKBIL1 C 4.11E-05 1.22
rs201458058 1q32.3 212142051 INTS7 - 4.12E-05 1.70
rs480092 6p21.33 31764899 VARS T 4.12E-05 1.31
Affx-52368556 6p21.33 31084936 CDSN - 4.18E-05 1.25
rs3129878 6p21.32 32408735 HLA-DRA A 4.46E-05 1.23
rs79192891 3q12.3 102470556 ZPLD1 T 4.54E-05 1.80
rs2596480 6p21.33 31425985 MICA C 4.59E-05 1.50
rs78374723 12q13.13 53096894 KRT77 T 4.63E-05 13.35
rs2508016 6p21.33 30969527 MUC22 C 4.63E-05 1.32
rs35157068 1q43 242762202 PLD5 T 4.65E-05 1.21
rs3129234 6p21.32 33111347 COL11A2 C 4.67E-05 1.26
rs1264708 6p22.1 30057154 TRIM31 A 4.79E-05 1.26
rs34976040 2q37.3 241401673 GPC1 A 4.80E-05 1.72
rs723872 20p13 1707027 SIRPG C 4.82E-05 1.34
rs1051790 6p21.33 31378956 MICA C 4.90E-05 1.32
rs2596460 6p21.33 31417510 MICA A 4.95E-05 1.50
Affx-28441669 6p21.33 31084075 CDSN G 5.07E-05 1.21
rs17015501 2p22.3 34906388 LINC01320 C 5.23E-05 1.26
rs3132499 6p21.33 31207920 HLA-C C 5.23E-05 1.28
Affx-80220121 2q37.3 242051776 PASK A 5.26E-05 1.35
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rs756440 6p21.32 33122331 COL11A2 A 5.27E-05 1.26
rs422640 6p22.1 29943005 HCG9 G 5.33E-05 1.31
rs3117294 6p22.1 29653329 HLA-F T 5.37E-05 1.22
rs3807031 6p22.1 30033884 PPP1R11 A 5.39E-05 1.25
rs743400 6p21.33 31607111 BAG6 A 5.53E-05 1.59
rs11933083 4q13.2 68114997 LOC101927237 G 5.64E-05 1.41
rs492899 6p21.33 31933518 SKIV2L T 5.64E-05 1.44
rs241455 6p21.32 32796019 TAP2 C 5.64E-05 1.24
rs9287104 1q32.1 199631525 NR5A2 G 5.66E-05 1.45
rs61748840 21q22.13 38563686 TTC3 G 5.70E-05 1.76
rs9276436 6p21.32 32714083 HLA-DQA2 T 5.98E-05 1.52
rs3130013 6p21.32 33313427 DAXX A 6.00E-05 1.33
rs4389802 6p21.32 32328237 C6orf10 A 6.01E-05 1.28
rs10796745 9q13 68242821 ANKRD20A3 C 6.06E-05 1.35
rs1130838 6p21.33 31237124 HLA-C T 6.19E-05 1.21
rs17088339 18q22.3 71476133 FBXO15 T 6.23E-05 1.41
rs150865922 12q13.11 48381394 COL2A1 A 6.36E-05 12.66
rs2239526 6p21.33 31509432 DDX39B G 6.40E-05 1.23
rs7744593 6p21.32 32704326 HLA-DQA2 A 6.47E-05 1.24
rs241439 6p21.32 32797537 TAP2 T 6.50E-05 1.21
rs86567 6p21.32 32976759 HLA-DOA G 6.53E-05 1.20
rs62132300 19p13.3 862355 CFD C 6.58E-05 1.23
rs3134931 6p21.32 32190620 NOTCH4 T 6.68E-05 1.23
rs56203327 8q12.1 60775976 CA8 G 6.71E-05 1.21
rs66485631 6p21.33 31083798 CDSN CTT 6.78E-05 1.20
rs7774954 6p21.32 32724189 HLA-DQB2 C 6.80E-05 1.52
rs3128955 6p21.32 33021192 HLA-DOA A 6.83E-05 1.24
rs2524276 6p21.33 31408265 MICA C 6.87E-05 1.54
rs202032329 17q23.2 60522293 METTL2A A 6.90E-05 1.53
rs174220 6p22.1 30017756 ZNRD1-AS1 A 6.97E-05 1.52
rs259942 6p22.1 30015167 ZNRD1-AS1 C 7.16E-05 1.30
rs3115537 6p21.33 31497835 MCCD1 G 7.48E-05 1.25
rs3129252 6p21.32 33108848 COL11A2 T 7.49E-05 1.25
rs1047099 20q13.33 61288038 SLCO4A1 G 7.50E-05 1.23
rs3130666 6p21.33 30740160 IER3 G 7.61E-05 1.85
rs7759909 6p21.33 31158689 PSORS1C3 G 7.88E-05 1.37
rs73605945 8p11.22 39468128 ADAM18 T 7.93E-05 19.18
rs3134782 6p21.33 31197633 HLA-C G 8.02E-05 1.27
rs3094216 6p21.33 31084048 CDSN G 8.07E-05 1.24
rs74268183 2q14.1 117105789 DPP10 C 8.17E-05 1.43
rs2075798 6p21.33 31846741 SLC44A4 C 8.24E-05 1.50
rs928822 6p22.1 30275246 HCG18 G 8.33E-05 1.20
rs1267481 6p23 14559080 JARID2 C 8.43E-05 1.25
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rs3131628 6p21.33 31502767 DDX39B C 8.64E-05 1.24
rs117131055 19p13.2 12780204 WDR83 C 8.80E-05 1.76
rs757262 6p22.1 30114955 TRIM40 T 8.85E-05 1.23
rs12722018 6p21.32 33048532 HLA-DPB1 G 8.91E-05 2.01
rs241437 6p21.32 32797684 TAP2 A 8.94E-05 1.21
rs2230103 7q22.1 101921289 CUX1 A 8.97E-05 1.68
rs10206572 2p25.3 3113710 LINC01250 C 9.05E-05 1.32
rs4337378 18q12.1 25393317 CHST9 C 9.07E-05 1.20
rs3097657 6p21.32 33006252 HLA-DOA T 9.07E-05 2.16
rs12142107 1p36.22 11097867 MASP2 T 9.10E-05 1.78
rs241447 6p21.32 32796751 TAP2 T 9.20E-05 1.24
rs13121311 4q34.1 172204876 GALNTL6 A 9.26E-05 1.24
rs72927046 6q16.1 96656753 FUT9 T 9.33E-05 1.60
rs707926 6p21.33 31748820 VARS G 9.47E-05 1.30
rs2309753 2q11.2 100775920 AFF3 C 9.53E-05 1.21
rs12003547 9p13.3 35891996 OR13J1 A 9.53E-05 1.23
rs241449 6p21.32 32796653 TAP2 C 9.57E-05 1.24
rs79523068 2p12 77051328 LRRTM4 T 9.57E-05 1.61
rs34785870 9q22.33 101555336 ANKS6 C 9.67E-05 1.36
rs7282216 21q22.3 47471324 COL6A1 A 9.70E-05 1.20
rs4480926 19p13.3 6127253 RFX2 C 9.73E-05 1.21
rs28587839 10q26.13 125849315 CHST15 T 9.78E-05 1.21
rs67605123 13q21.33 71486708 LINC00348 G 9.85E-05 1.23
rs3093978 6p21.33 31498497 DDX39B C 9.89E-05 1.24
rs77239684 5p15.2 14265029 TRIO T 9.90E-05 1.39
rs6111080 20p13 1689231 SIRPG T 9.92E-05 1.30
Legend: Association data are shown for all SNPs achieving Eigenstrat P values < 1.0 x 10-4.
Affymetrix SNP IDs are provided for SNPs with no available rs ID.
ANCA = anti-neutrophil cyctoplasmic antibody; OR = odds ratio.
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rs141530233 6p21.32 33048688 HLA-DPB1 - 1.69E-68 6.06
rs1042169 6p21.32 33048686 HLA-DPB1 G 1.94E-68 5.98
rs1071597 6p21.32 33052986 HLA-DPB1 T 3.75E-65 6.14
rs9277554 6p21.32 33055538 HLA-DPB1 C 9.46E-65 6.06
rs9277498 6p21.32 33054141 HLA-DPB1 T 1.13E-64 5.92
rs9277546 6p21.32 33055346 HLA-DPB1 T 1.24E-64 5.92
rs9277410 6p21.32 33051640 HLA-DPB1 G 1.35E-64 5.92
rs2064476 6p21.32 33073322 HLA-DPB1 A 1.47E-64 5.87
rs9277471 6p21.32 33053682 HLA-DPB1 G 1.48E-64 5.91
rs9277424 6p21.32 33051865 HLA-DPB1 A 1.53E-64 5.91
rs9277514 6p21.32 33054235 HLA-DPB1 T 2.21E-64 5.90
rs1042335 6p21.32 33052958 HLA-DPB1 C 9.74E-64 5.86
rs1431403 6p21.32 33047031 HLA-DPB1 T 9.83E-61 5.83
rs2144014 6p21.32 33065813 HLA-DPB1 G 1.81E-57 6.64
rs3128927 6p21.32 33074288 HLA-DPB1 C 2.25E-56 5.44
rs3117223 6p21.32 33060064 HLA-DPB1 G 2.62E-56 6.62
rs2395314 6p21.32 33062673 HLA-DPB1 G 3.32E-56 6.68
rs3128917 6p21.32 33059996 HLA-DPB1 T 3.33E-56 6.61
rs3130190 6p21.32 33061690 HLA-DPB1 T 1.57E-55 6.41
rs3117231 6p21.32 33074908 HLA-DPB1 A 1.30E-54 6.56
rs3128921 6p21.32 33070749 HLA-DPB1 C 3.42E-54 6.37
rs9277464 6p21.32 33053352 HLA-DPB1 C 2.21E-52 5.39
rs9277535 6p21.32 33054861 HLA-DPB1 A 2.55E-52 5.38
rs9277489 6p21.32 33053942 HLA-DPB1 T 5.99E-52 5.26
rs9277341 6p21.32 33039625 HLA-DPA1 T 3.91E-50 3.44
rs3135024 6p21.32 33047466 HLA-DPB1 T 7.08E-50 5.18
rs2179920 6p21.32 33058874 HLA-DPB1 C 2.29E-47 6.42
rs2064474 6p21.32 33073463 HLA-DPB1 G 3.24E-47 5.89
rs3117230 6p21.32 33075635 HLA-DPB1 A 8.39E-47 5.98
rs2064478 6p21.32 33072266 HLA-DPB1 C 1.03E-46 5.97
rs1042153 6p21.32 33048663 HLA-DPB1 G 2.34E-46 6.59
rs910320 6p21.32 33075443 HLA-DPB1 C 7.28E-45 5.83
rs9277567 6p21.32 33057013 HLA-DPB1 A 3.89E-44 6.10
rs1126513 6p21.32 33048467 HLA-DPB1 G 4.03E-44 4.81
rs1042151 6p21.32 33048661 HLA-DPB1 A 2.10E-40 7.44
rs2281389 6p21.32 33059796 HLA-DPB1 A 2.59E-36 5.90
rs2071025 6p21.32 33143756 COL11A2 A 5.95E-36 3.12
rs439205 6p21.32 33173842 HSD17B8 G 8.69E-36 3.12
rs1042434 6p21.32 33036505 HLA-DPA1 G 3.05E-35 4.93
rs2076310 6p21.32 33166034 RXRB A 3.40E-35 3.04
rs3077 6p21.32 33033022 HLA-DPA1 A 7.99E-35 4.88
Affx-28512827 6p21.32 33037424 HLA-DPA1 T 1.44E-34 4.84
rs3097671 6p21.32 33047612 HLA-DPB1 G 1.56E-34 5.79
rs10214910 6p21.32 33037675 HLA-DPA1 C 1.87E-34 4.84
Affx-28512796 6p21.32 33036853 HLA-DPA1 A 2.50E-34 4.77
rs2308911 6p21.32 33037580 HLA-DPA1 T 2.70E-34 4.82
rs17214533 6p21.32 33032272 HLA-DOA C 3.18E-34 4.86
rs1431399 6p21.32 33041034 HLA-DPA1 A 4.03E-34 4.63
rs9277935 6p21.32 33160425 COL11A2 G 5.76E-32 3.15
rs213209 6p21.32 33176958 RING1 C 6.26E-32 2.50
rs421446 6p21.32 33174783 HSD17B8 A 1.36E-31 2.43
rs1126769 6p21.32 33036435 HLA-DPA1 T 2.03E-31 4.25
Supplementary Table 5. Results of genome-wide association analysis for PR3-
ANCA/cANCA-associated vasculitis.
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rs1042190 6p21.32 33036999 HLA-DPA1 T 7.05E-30 4.51
rs2858458 6p21.32 33003065 HLA-DOA T 1.20E-28 2.40
rs3117016 6p21.32 33095516 HLA-DPB2 G 2.97E-28 1.98
rs1126543 6p21.32 33037419 HLA-DPA1 G 6.97E-28 3.44
rs3130161 6p21.32 33125858 COL11A2 A 3.94E-26 5.07
rs987870 6p21.32 33042880 HLA-DPA1 A 4.40E-26 4.22
rs2071352 6p21.32 33044188 HLA-DPB1 T 5.40E-26 5.05
rs439121 6p21.32 33192867 RING1 A 1.19E-24 2.19
rs3129270 6p21.32 33097423 COL11A2 C 5.23E-23 4.60
rs986521 6p21.32 33136145 COL11A2 G 6.32E-23 1.77
rs2855459 6p21.32 33154656 COL11A2 G 4.07E-22 3.26
rs213212 6p21.32 33185918 RING1 C 8.67E-22 1.75
rs213213 6p21.32 33183730 RING1 T 1.14E-21 1.71
rs9277946 6p21.32 33194717 RING1 C 1.91E-21 3.12
rs2855442 6p21.32 33137403 COL11A2 C 2.38E-21 1.71
rs213194 6p21.32 33195604 RING1 A 3.44E-21 1.72
rs2855425 6p21.32 33144373 COL11A2 G 3.81E-21 1.71
rs6531 6p21.32 33163451 RXRB G 7.84E-21 1.71
rs3116994 6p21.32 33098797 COL11A2 G 3.07E-20 1.67
rs2744512 6p21.32 33141920 COL11A2 G 4.16E-20 1.71
rs3116999 6p21.32 33097166 COL11A2 G 7.31E-20 2.42
rs3129207 6p21.32 33125312 COL11A2 G 5.67E-19 1.64
rs1883414 6p21.32 33086448 HLA-DPB2 G 7.80E-19 1.79
rs3129294 6p21.32 33084671 HLA-DPB2 A 5.31E-18 1.69
Affx-52341735 6p21.32 33138955 COL11A2 G 6.65E-18 1.63
rs3117008 6p21.32 33096274 HLA-DPB2 G 7.02E-18 1.61
rs7772134 6p21.32 33049726 HLA-DPB1 G 3.53E-17 4.07
rs2294479 6p21.32 33098389 COL11A2 G 6.15E-17 1.71
rs2855437 6p21.32 33138955 COL11A2 G 4.69E-15 1.55
rs3097669 6p21.32 33023792 HLA-DOA A 5.11E-15 1.77
rs3129274 6p21.32 33094869 HLA-DPB2 C 2.31E-14 1.54
rs3129267 6p21.32 33098896 COL11A2 C 2.80E-14 1.53
rs2855448 6p21.32 33136575 COL11A2 C 2.39E-12 1.47
rs35242582 6p21.32 32600057 HLA-DQA1 A 2.43E-12 1.63
rs2254287 6p21.32 33143948 COL11A2 C 3.27E-12 1.50
rs726599 6p21.32 33121678 COL11A2 C 9.60E-12 1.46
rs429916 6p21.32 32978587 HLA-DOA C 2.01E-11 2.88
rs2257126 6p21.32 33131734 COL11A2 A 2.32E-11 1.45
rs763469 6p21.32 33004387 HLA-DOA A 3.10E-11 1.57
Affx-28513472 6p21.32 33053577 HLA-DPB1 G 5.68E-11 6.98
rs3130604 6p21.32 32985052 HLA-DOA G 6.20E-11 1.56
rs62132293 19p13.3 838178 PRTN3 G 7.92E-10 1.41
rs3129304 6p21.32 32973743 HLA-DOA C 9.10E-10 1.51
rs28584179 6p21.32 32626119 HLA-DQA1 C 1.00E-09 2.01
rs116518618 6p21.32 32594998 HLA-DRB1 C 1.26E-09 2.00
rs3130176 6p21.32 33017457 HLA-DOA A 1.88E-09 1.38
rs1810472 6p21.32 33083121 HLA-DPB2 T 2.46E-09 1.46
rs211449 6p21.32 33333916 DAXX G 3.20E-09 1.42
rs213210 6p21.32 33175824 RING1 A 3.91E-09 2.49
rs9468925 6p21.33 31258837 HLA-C G 4.41E-09 1.41
rs423639 6p21.32 32987774 HLA-DOA C 6.46E-09 2.24
rs3129264 6p21.32 33101602 COL11A2 A 6.51E-09 1.51
rs28929474 14q32.13 94844947 SERPINA1 T 6.82E-09 2.38
rs206762 6p21.32 32970450 BRD2 G 7.04E-09 1.37
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rs2068204 6p21.32 33058718 HLA-DPB1 G 9.13E-09 7.14
rs9368758 6p21.32 33138021 COL11A2 G 9.20E-09 2.42
rs1882 6p21.33 31382911 MICA A 9.78E-09 1.38
rs3097648 6p21.32 32990970 HLA-DOA A 1.17E-08 1.78
rs3129234 6p21.32 33111347 COL11A2 C 1.29E-08 1.50
rs756440 6p21.32 33122331 COL11A2 A 1.33E-08 1.49
rs3117034 6p21.32 33087358 HLA-DPB2 T 1.45E-08 1.38
rs3094672 6p21.33 30993377 MUC22 T 1.72E-08 1.40
rs3129258 6p21.32 33105469 COL11A2 G 1.80E-08 1.49
rs3130257 6p21.32 33256471 WDR46 T 2.03E-08 1.55
rs605203 6p21.33 31847012 EHMT2 C 2.22E-08 1.37
rs3129252 6p21.32 33108848 COL11A2 T 2.32E-08 1.48
rs486416 6p21.33 31856070 EHMT2 G 3.20E-08 1.36
rs9380343 6p21.32 33079166 HLA-DPB1 C 3.44E-08 4.89
rs3873386 6p21.33 31273745 HLA-C T 3.69E-08 1.38
rs2281390 6p21.32 33059669 HLA-DPB1 T 3.71E-08 1.43
rs2596530 6p21.33 31387373 MICA G 4.73E-08 1.36
rs2524040 6p21.33 31257625 HLA-C T 4.86E-08 1.36
rs2256183 6p21.33 31380529 MICA A 5.68E-08 1.36
rs659445 6p21.33 31864304 EHMT2 G 5.85E-08 1.36
rs535586 6p21.33 31860337 EHMT2 T 9.60E-08 1.35
rs9296068 6p21.32 32988695 HLA-DOA T 1.06E-07 1.38
rs440454 6p21.33 31927342 SKIV2L A 1.08E-07 1.36
Affx-28512853 6p21.32 33037640 HLA-DPA1 C 1.43E-07 5.57
rs3132454 6p21.33 31489644 MCCD1 A 1.60E-07 1.37
rs419788 6p21.33 31928799 SKIV2L T 1.68E-07 1.35
rs6936620 6p21.32 32984451 HLA-DOA A 1.69E-07 1.33
rs176248 6p21.32 32965942 BRD2 G 1.81E-07 1.42
rs3905495 6p21.33 31265539 HLA-C G 1.86E-07 1.37
rs805284 6p21.33 31682029 LY6G6D A 2.23E-07 1.79
rs448733 6p21.32 33003687 HLA-DOA C 2.32E-07 2.52
rs1062481 6p21.32 33037611 HLA-DPA1 C 2.41E-07 5.41
rs213226 6p21.32 33209310 RING1 A 2.79E-07 1.32
rs437179 6p21.33 31929014 SKIV2L A 3.03E-07 1.35
rs2247056 6p21.33 31265490 HLA-C T 3.16E-07 1.37
rs630379 6p21.33 31922254 NELFE A 3.25E-07 1.35
rs6457374 6p21.33 31272261 HLA-C C 4.49E-07 1.35
rs211450 6p21.32 33333446 DAXX C 5.06E-07 1.34
rs6899309 6p21.32 32915823 HLA-DMB T 6.17E-07 2.27
rs2853931 6p21.33 31255007 HLA-C C 6.48E-07 1.31
rs3129299 6p21.32 32900787 HLA-DMB C 6.57E-07 1.52
rs67523850 6p21.32 33054014 HLA-DPB1 A 6.90E-07 2.71
rs6937034 6p21.32 33079766 HLA-DPB1 A 7.22E-07 5.05
rs75549913 6p21.33 31390139 MICA - 7.22E-07 1.33
rs389883 6p21.33 31947460 STK19 G 7.42E-07 1.33
rs3130609 6p21.32 32989521 HLA-DOA C 7.81E-07 3.67
rs423209 6p21.32 32983474 HLA-DOA G 8.00E-07 3.21
rs9263873 6p21.33 31170713 HCG27 T 8.94E-07 1.32
rs3873444 6p21.32 32682724 HLA-DQA2 C 1.04E-06 1.67
rs7264431 20p13 1716975 SIRPG C 1.09E-06 1.52
rs9277348 6p21.32 33048538 HLA-DPB1 T 1.13E-06 7.56
rs1049526 6p21.32 32948804 BRD2 C 1.18E-06 1.51
rs429608 6p21.33 31930462 SKIV2L G 1.21E-06 1.51
rs1042149 6p21.33 31082960 CDSN A 1.22E-06 1.31
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rs1050391 6p21.32 32917857 HLA-DMA A 1.35E-06 1.51
rs9366814 6p21.32 33080799 HLA-DPB2 T 1.37E-06 4.28
rs6928399 6p21.33 31195218 HLA-C C 1.41E-06 1.34
rs9348906 6p21.32 33080360 HLA-DPB2 T 1.43E-06 4.87
rs3094212 6p21.33 31085770 CDSN G 1.47E-06 1.31
rs3130320 6p21.32 32223258 NOTCH4 T 1.49E-06 1.31
rs4713447 6p21.33 31162963 PSORS1C3 A 1.51E-06 1.31
rs3135029 6p21.32 32921774 BRD2 T 1.60E-06 1.50
rs3132554 6p21.33 31084163 CDSN A 1.63E-06 1.31
rs213220 6p21.32 33202640 RING1 C 1.71E-06 1.30
rs9277193 6p21.32 33023880 HLA-DOA T 1.89E-06 1.30
rs4713422 6p21.33 30999902 MUC22 G 1.96E-06 1.32
rs3129287 6p21.32 33089104 HLA-DPB2 G 1.96E-06 1.37
rs2853933 6p21.33 31254088 HLA-C T 2.02E-06 1.30
rs3134926 6p21.32 32200147 NOTCH4 C 2.27E-06 1.35
rs9380345 6p21.32 33080359 HLA-DPB2 C 2.28E-06 4.42
rs10947121 6p21.33 30999997 MUC22 T 2.62E-06 1.32
Affx-28441669 6p21.33 31084075 CDSN G 2.65E-06 1.30
rs3129305 6p21.32 32959180 BRD2 G 2.74E-06 1.49
rs2524163 6p21.33 31259579 HLA-C C 2.88E-06 1.29
rs3130597 6p21.32 32941191 BRD2 T 3.12E-06 1.49
rs3129297 6p21.32 32927969 BRD2 A 3.16E-06 1.49
rs3097644 6p21.32 32945530 BRD2 G 3.49E-06 1.50
rs2070600 6p21.32 32151443 AGER T 3.53E-06 1.67
rs2524089 6p21.33 31266522 HLA-C G 3.55E-06 1.29
rs2844514 6p21.33 31380340 MICA C 3.57E-06 1.30
rs2243868 6p21.33 31261276 HLA-C A 3.75E-06 1.29
rs9271897 6p21.32 32595954 HLA-DRB1 G 3.95E-06 1.28
rs12664430 6p21.32 33272677 TAPBP T 3.95E-06 1.54
rs6936204 6p21.32 32217092 NOTCH4 T 4.07E-06 1.30
rs2844513 6p21.33 31388214 MICA G 4.11E-06 1.30
rs66485631 6p21.33 31083798 CDSN CTT 4.26E-06 1.29
rs34892006 6p22.1 29012712 OR2W1 C 4.66E-06 10.85
rs9273088 6p21.32 32612488 HLA-DQA1 C 5.15E-06 1.29
rs541862 6p21.33 31916951 CFB T 6.14E-06 1.66
rs6679677 1p13.2 114303808 PTPN22 A 6.16E-06 1.46
rs117131055 19p13.2 12780204 WDR83 C 6.20E-06 2.04
rs1130838 6p21.33 31237124 HLA-C T 6.32E-06 1.29
rs12722018 6p21.32 33048532 HLA-DPB1 G 6.65E-06 3.40
rs3132680 6p22.1 30073195 TRIM31 A 6.66E-06 1.30
rs2853939 6p21.33 31250642 HLA-C T 6.86E-06 1.27
rs2230693 21q22.3 46913477 COL18A1 C 7.90E-06 4.83
rs16935391 10q21.1 54680402 MBL2 A 8.51E-06 1.48
rs2116263 6p21.32 33025493 HLA-DOA G 8.56E-06 7.66
rs213199 6p21.32 33235755 VPS52 G 8.59E-06 1.29
rs206018 6p21.32 32177880 NOTCH4 C 9.28E-06 1.42
rs3128955 6p21.32 33021192 HLA-DOA A 9.38E-06 1.32
rs438999 6p21.33 31928306 SKIV2L A 9.50E-06 1.63
rs3115572 6p21.32 32220484 NOTCH4 C 9.61E-06 1.28
rs1130368 6p21.32 32632818 HLA-DQB1 T 9.78E-06 1.42
rs3134931 6p21.32 32190620 NOTCH4 T 1.04E-05 1.31
rs3132499 6p21.33 31207920 HLA-C C 1.05E-05 1.37
rs2524074 6p21.33 31244021 HLA-C G 1.05E-05 1.29
rs3135195 6p21.32 32999330 HLA-DOA T 1.14E-05 3.19
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rs146599962 18q21.31 55398906 ATP8B1 G 1.17E-05 16.91
rs3130171 6p21.32 32998729 HLA-DOA T 1.19E-05 1.29
rs1634717 6p21.33 30972589 MUC22 G 1.23E-05 1.27
rs213202 6p21.32 33232055 VPS52 G 1.29E-05 1.29
rs213204 6p21.32 33241076 RPS18 C 1.32E-05 1.29
rs805287 6p21.33 31678730 LY6G6F A 1.41E-05 1.31
rs12003547 9p13.3 35891996 OR13J1 A 1.42E-05 1.31
rs34877619 5q15 97466217 RGMB G 1.65E-05 1.31
rs2394734 6p22.1 30046246 TRIM31 G 1.67E-05 1.39
rs3129883 6p21.32 32410137 HLA-DRA T 1.67E-05 1.29
rs7720359 5q15 97440378 RGMB G 1.72E-05 1.31
rs9262549 6p21.33 30997692 MUC22 G 1.82E-05 1.28
rs9271824 6p21.32 32594916 HLA-DRB1 A 1.83E-05 1.26
rs2272592 6p21.33 31698352 CLIC1 T 1.90E-05 1.32
rs382259 6p21.32 32209027 NOTCH4 T 1.95E-05 1.32
rs12722027 6p21.32 33048641 HLA-DPB1 A 2.03E-05 3.08
rs9273215 6p21.32 32613712 HLA-DQA1 A 2.06E-05 1.27
rs389512 6p21.33 31947594 STK19 G 2.13E-05 1.48
rs3130013 6p21.32 33313427 DAXX A 2.15E-05 1.42
rs2233385 2q37.1 233897503 NEU2 A 2.17E-05 3.17
rs3134604 6p21.32 32122386 PPT2 C 2.23E-05 1.36
rs9274552 6p21.32 32634838 HLA-DQB1 C 2.24E-05 1.27
rs4807840 19p13.3 6156483 ACSBG2 C 2.27E-05 1.29
rs4412248 6p21.32 33072415 HLA-DPB1 C 2.33E-05 11.91
rs7382297 6p21.33 31247067 HLA-C T 2.38E-05 1.35
rs1143260 6p21.32 32359227 HCG23 A 2.40E-05 1.49
rs2523644 6p21.33 31342484 MICA C 2.40E-05 1.33
rs78374723 12q13.13 53096894 KRT77 T 2.44E-05 15.79
rs117566511 19p13.2 12805424 FBXW9 T 2.44E-05 1.94
rs411337 6p21.33 32077380 ATF6B C 2.46E-05 1.67
rs3134782 6p21.33 31197633 HLA-C G 2.53E-05 1.34
rs3130952 6p21.33 31177915 HLA-C G 2.70E-05 1.35
rs3094609 6p21.33 31165566 HCG27 T 2.72E-05 1.34
rs4248153 6p21.33 31002527 MUC22 A 2.80E-05 1.27
rs9267649 6p21.33 31824828 NEU1 A 2.81E-05 1.32
rs3130933 6p21.33 31132085 TCF19 T 2.83E-05 1.36
rs3117294 6p22.1 29653329 HLA-F T 2.84E-05 1.28
rs3873379 6p21.33 31262169 HLA-C T 2.85E-05 1.30
rs7041467 9q21.32 85865570 FRMD3 G 2.85E-05 5.93
rs2476601 1p13.2 114377568 PTPN22 (R620W) A 2.92E-05 1.42
rs34182778 6p21.33 31084943 CDSN - 2.95E-05 1.32
rs9274407 6p21.32 32632832 HLA-DQB1 A 2.99E-05 1.33
rs2517424 6p21.33 30949996 MUC21 T 3.06E-05 1.43
rs28367630 6p21.33 31267934 HLA-C A 3.17E-05 1.29
rs453590 6p21.32 33403422 SYNGAP1 C 3.22E-05 1.26
rs56291618 7p22.3 164282 FAM20C A 3.25E-05 2.14
rs2844795 6p22.1 30073847 TRIM31 C 3.27E-05 1.26
rs2857107 6p21.32 32785515 HLA-DOB C 3.28E-05 1.49
rs76416341 1p36.32 3679783 CCDC27 C 3.34E-05 23.77
rs1800454 6p21.32 32800412 TAP2 T 3.34E-05 1.35
rs1894411 6p21.32 32792973 TAP2 T 3.38E-05 1.49
rs2246638 6p22.1 29949497 HCG9 G 3.47E-05 1.36
rs1063355 6p21.32 32627714 HLA-DQB1 G 3.47E-05 1.26
rs2240070 6p22.1 30071110 TRIM31 T 3.53E-05 1.27
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rs17843619 6p21.32 32620775 HLA-DQA1 A 3.74E-05 1.26
rs3097657 6p21.32 33006252 HLA-DOA T 3.82E-05 3.19
rs1780735 1p31.1 79209403 IFI44 G 3.86E-05 1.35
rs17612576 6p21.32 32615458 HLA-DQA1 A 3.95E-05 1.26
rs3129888 6p21.32 32411726 HLA-DRA G 4.22E-05 1.30
rs204888 6p21.33 32089142 ATF6B G 4.59E-05 1.64
rs1051790 6p21.33 31378956 MICA C 4.67E-05 1.40
rs2596501 6p21.33 31321211 HLA-C C 4.69E-05 1.25
rs2808096 10p11.22 32128611 ARHGAP12 A 4.70E-05 1.33
Affx-28465058 6p21.33 31936679 SKIV2L C 4.74E-05 1.45
rs210120 6p21.31 33574413 ITPR3 A 4.75E-05 1.25
rs2596548 6p21.33 31330546 MICA T 4.87E-05 1.32
rs723872 20p13 1707027 SIRPG C 4.88E-05 1.40
rs34196598 7q22.1 100636147 MUC12 C 4.96E-05 1.45
rs10190766 2p13.2 72366818 CYP26B1 T 4.97E-05 1.78
rs241438 6p21.32 32797620 TAP2 C 4.99E-05 1.27
rs213203 6p21.32 33238404 VPS52 A 5.03E-05 1.25
Affx-28507878 6p21.32 32823948 PSMB9 G 5.11E-05 2.92
rs139817454 12q13.3 57000083 BAZ2A T 5.18E-05 15.90
rs3129301 6p21.32 32990060 HLA-DOA G 5.19E-05 3.13
rs1241983 18p11.31 6875693 ARHGAP28 A 5.21E-05 1.25
rs3130014 6p21.32 33312308 DAXX A 5.22E-05 1.28
rs3104402 6p21.32 32681676 HLA-DQB1 T 5.25E-05 1.47
rs3093983 6p21.33 31496925 MCCD1 G 5.38E-05 1.30
rs12184990 14q32.13 95253783 DICER1 T 5.40E-05 1.38
rs2228396 6p21.32 32797809 TAP2 T 5.58E-05 1.43
rs29234 6p22.1 29624112 GABBR1 A 5.66E-05 1.84
rs2395296 6p21.32 32911814 HLA-DMB A 5.77E-05 1.26
rs423808 6p22.1 29949123 HCG9 G 5.81E-05 1.44
rs444921 6p21.33 31932177 SKIV2L C 5.85E-05 1.45
rs3130118 6p22.1 30365740 HLA-E C 5.95E-05 1.26
rs61730696 17q21.2 40831684 CCR10 A 5.95E-05 8.64
rs17271707 2q34 213510374 ERBB4 A 5.96E-05 1.29
rs3131283 6p21.32 32119898 PRRT1 T 6.04E-05 1.34
rs387608 6p21.33 31941557 STK19 G 6.20E-05 1.44
rs2693726 7q32.2 129417679 UBE2H T 6.25E-05 1.25
rs10213293 4p15.2 23123472 GBA3 G 6.25E-05 1.26
rs1265048 6p21.33 31081409 PSORS1C1 T 6.35E-05 1.27
rs1800684 6p21.32 32151994 AGER A 6.44E-05 1.33
rs4480926 19p13.3 6127253 RFX2 C 6.53E-05 1.26
rs887466 6p21.33 31143511 PSORS1C3 G 6.80E-05 1.26
rs7738815 6p21.32 33020387 HLA-DOA G 6.80E-05 4.00
rs9261895 6p22.1 30389323 HLA-E T 6.98E-05 1.33
rs9264643 6p21.33 31238492 HLA-C C 7.07E-05 1.25
rs1265155 6p21.33 31143694 PSORS1C3 G 7.23E-05 1.26
rs4668338 2q31.1 171733225 GAD1 C 7.23E-05 7.56
rs17260787 5p15.2 13644978 DNAH5 T 7.28E-05 1.54
rs10859638 12q22 94433035 CRADD G 7.41E-05 1.31
Affx-28452229 6p21.33 31322303 HLA-B C 7.51E-05 1.26
rs11933083 4q13.2 68114997 LOC101927237 G 7.55E-05 1.47
rs13043804 20q13.31 55375403 BMP7 C 7.65E-05 1.27
rs199556640 6p21.32 32609299 HLA-DQA1 - 7.71E-05 1.24
rs4713668 6p21.31 33690796 IP6K3 T 7.98E-05 1.24
rs700726 8q12.1 60931328 CA8 T 8.00E-05 1.25
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rs2384114 10q21.1 54831767 MBL2 C 8.06E-05 1.29
rs61745073 14q12 24798433 ADCY4 A 8.08E-05 7.29
rs2227956 6p21.33 31778272 HSPA1L G 8.11E-05 1.29
rs2535260 6p22.1 29628883 MOG C 8.51E-05 1.32
rs41267649 6p21.32 33384473 CUTA T 8.90E-05 1.86
rs7573071 2q36.3 228043161 COL4A3 C 8.99E-05 1.42
rs29272 6p22.1 29618366 GABBR1 G 9.04E-05 1.81
rs34229432 20q13.31 55700904 BMP7 G 9.06E-05 1.49
rs10121214 9p24.3 1919789 SMARCA2 C 9.39E-05 1.25
rs1265109 6p21.33 31119589 CCHCR1 G 9.42E-05 1.29
rs3132946 6p21.32 32190028 NOTCH4 A 9.50E-05 1.33
rs3131631 6p21.33 31484683 MCCD1 G 9.61E-05 1.27
rs3132469 6p21.33 31456567 MICB A 9.73E-05 1.33
rs62640032 17p13.3 902802 TIMM22 A 9.79E-05 1.65
rs7381988 6p21.33 31246703 HLA-C G 9.80E-05 1.31
rs2523554 6p21.33 31331829 MICA C 9.89E-05 1.24
rs73605945 8p11.22 39468128 ADAM18 T 9.92E-05 19.85
rs211474 6p21.32 33320613 DAXX G 9.94E-05 1.26
Legend: Association data are shown for all SNPs achieving Eigenstrat P values < 1.0 x 10-4.
Affymetrix SNP IDs are provided for SNPs with no available rs ID.
ANCA = anti-neutrophil cytoplasmic antibody; PR3 = proteinase 3; cANCA = cytoplasmic ANCA; OR = odds ratio
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rs3998159 6p21.32 32682019 HLA-DQA2 C 3.47E-19 2.61
rs7454108 6p21.32 32681483 HLA-DQA2 C 3.90E-19 2.61
rs1049072 6p21.32 32634355 HLA-DQB1 A 1.63E-18 2.27
rs9275184 6p21.32 32654714 HLA-DQA2 C 2.29E-18 2.55
rs1130399 6p21.32 32629755 HLA-DQB1 A 1.24E-17 2.22
rs660895 6p21.32 32577380 HLA-DRB1 G 1.94E-17 2.18
rs2395175 6p21.32 32405026 HLA-DRA A 2.17E-14 2.09
rs115360810 6p21.32 32796310 TAP2 G 2.56E-14 3.55
rs6910071 6p21.32 32282854 C6orf10 G 9.12E-12 1.90
rs2395163 6p21.32 32387809 HLA-DRA C 1.09E-10 1.80
rs3793127 6p21.32 32371915 BTNL2 T 1.40E-10 1.79
rs34252386 6p21.32 32546912 HLA-DRB1 G 3.29E-10 1.71
rs35445101 6p21.32 32546879 HLA-DRB1 G 4.97E-10 1.70
rs9268923 6p21.32 32432835 HLA-DRB5 T 1.72E-09 1.67
rs2395185 6p21.32 32433167 HLA-DRB5 T 4.19E-09 1.66
rs28366302 6p21.32 32560934 HLA-DRB1 C 5.92E-09 1.65
rs9271897 6p21.32 32595954 HLA-DRB1 G 8.81E-09 1.63
rs9271824 6p21.32 32594916 HLA-DRB1 A 1.75E-08 1.62
rs34892006 6p22.1 29012712 OR2W1 C 2.14E-08 21.18
rs9272105 6p21.32 32599999 HLA-DRB1 G 2.81E-08 1.60
rs9275440 6p21.32 32671596 HLA-DQA2 T 5.23E-08 1.64
rs9267954 6p21.32 32213052 NOTCH4 T 5.92E-08 1.64
rs3916765 6p21.32 32685550 HLA-DQA2 A 3.37E-07 1.76
rs4642516 6p21.32 32657543 HLA-DQA2 T 4.00E-07 1.54
rs6679677 1p13.2 114303808 PTPN22 A 4.63E-07 1.81
rs373169384 9q34.3 139943388 ENTPD2 T 4.63E-07 3.96
rs5020946 6p21.32 32450089 HLA-DRB5 T 5.39E-07 1.54
rs28366353 6p21.32 32565004 HLA-DRB1 G 6.70E-07 1.51
rs9272116 6p21.32 32600404 HLA-DQA1 T 8.43E-07 1.51
rs7764856 6p21.32 32680640 HLA-DQA2 A 1.38E-06 1.52
rs6928482 6p21.32 32626249 HLA-DQA1 C 2.52E-06 1.49
rs10796745 9q13 68242821 ANKRD20A3 C 2.69E-06 1.78
rs9274697 6p21.32 32637016 HLA-DQB1 G 2.93E-06 1.47
rs2073044 6p21.32 32338986 C6orf10 T 3.67E-06 1.53
rs2476601 1p13.2 114377568 PTPN22 (R620W) A 3.76E-06 1.73
rs9273088 6p21.32 32612488 HLA-DQA1 C 3.94E-06 1.50
rs35242582 6p21.32 32600057 HLA-DQA1 A 4.15E-06 1.65
rs3134996 6p21.32 32636866 HLA-DQB1 T 4.30E-06 1.52
rs2857605 6p21.33 31524851 NFKBIL1 C 4.71E-06 1.54
rs5026743 6p21.32 32439964 HLA-DRB5 T 4.71E-06 1.49
rs9268877 6p21.32 32431147 HLA-DRB5 G 4.91E-06 1.48
rs1129808 6p21.32 32609312 HLA-DQA1 C 5.08E-06 1.49
rs9273215 6p21.32 32613712 HLA-DQA1 A 5.11E-06 1.49
rs199556640 6p21.32 32609299 HLA-DQA1 - 5.28E-06 1.49
rs3134926 6p21.32 32200147 NOTCH4 C 5.32E-06 1.58
rs2269475 6p21.33 31583931 AIF1 T 6.20E-06 1.64
rs17612576 6p21.32 32615458 HLA-DQA1 A 6.91E-06 1.48
rs67529500 6p21.32 32504757 HLA-DRB5 G 7.02E-06 1.49
rs3817966 6p21.32 32367847 BTNL2 C 7.02E-06 1.47
rs2075800 6p21.33 31777946 HSPA1L T 7.15E-06 1.47
rs1063355 6p21.32 32627714 HLA-DQB1 G 7.28E-06 1.48
rs73727981 6p21.32 32511791 HLA-DRB5 A 7.48E-06 1.49
Supplementary Table 6. Results of genome-wide association analysis for MPO-ANCA/pANCA-
associated vasculitis 
Page 57 of 69
John Wiley & Sons
Arthritis & Rheumatology











SNP Chromosome Position Gene Risk allele P  value OR
rs11138651 9q21.31 83021572 Intergenic T 7.89E-06 1.59
rs3096702 6p21.32 32192331 NOTCH4 A 8.15E-06 1.45
rs9274552 6p21.32 32634838 HLA-DQB1 C 8.51E-06 1.48
rs9268839 6p21.32 32428772 HLA-DRB5 G 8.92E-06 1.46
rs77127003 9q22.1 90500189 SPATA31E1 G 9.68E-06 2.15
rs77696001 21q21.2 25412718 LOC101927869 T 9.98E-06 1.79
rs9268480 6p21.32 32363844 BTNL2 T 1.01E-05 1.47
rs143952489 20q13.33 61525253 DIDO1 T 1.01E-05 21.74
rs9272346 6p21.32 32604372 HLA-DQA1 A 1.02E-05 1.46
rs9268428 6p21.32 32344973 C6orf10 T 1.11E-05 1.47
rs2295665 6p21.33 31632686 GPANK1 T 1.12E-05 1.62
rs4800027 18q12.2 36116229 MIR4318 G 1.25E-05 1.94
rs2242657 6p21.33 31602489 PRRC2A C 1.29E-05 1.61
rs2071295 6p21.33 32038700 TNXB T 1.29E-05 1.45
rs2077102 6p21.33 31611840 BAG6 A 1.30E-05 1.61
rs1419673 6p22.1 30096717 TRIM40 G 1.33E-05 1.50
rs17843606 6p21.32 32620399 HLA-DQA1 T 1.47E-05 1.46
rs9261485 6p22.1 30108751 TRIM40 A 1.52E-05 1.49
rs9268474 6p21.32 32357165 C6orf10 C 1.57E-05 1.46
rs3749981 6p21.32 32862682 LOC100294145 T 1.57E-05 1.75
rs261946 6p22.1 30271334 HCG18 G 1.57E-05 1.47
rs3763316 6p21.32 32376746 HLA-DRA T 1.59E-05 1.46
rs76250508 6p21.33 32010272 TNXB A 1.69E-05 1.45
rs757262 6p22.1 30114955 TRIM40 T 1.72E-05 1.49
rs2242655 6p21.33 31627449 C6orf47 G 1.79E-05 1.60
rs4151657 6p21.33 31917540 CFB C 1.82E-05 1.44
rs790604 6q15 91105349 MAP3K7 C 1.84E-05 1.93
rs1882 6p21.33 31382911 MICA A 1.93E-05 1.44
rs10766484 11p15.1 18539930 TSG101 T 1.93E-05 1.50
rs261945 6p22.1 30272417 HCG18 C 1.94E-05 1.44
rs757259 6p22.1 30115542 TRIM40 A 2.06E-05 1.48
rs3807031 6p22.1 30033884 PPP1R11 A 2.08E-05 1.50
rs17843619 6p21.32 32620775 HLA-DQA1 A 2.10E-05 1.45
rs2736428 6p21.33 31843924 SLC44A4 T 2.11E-05 1.44
rs1394363 14q24.3 77596653 CIPC T 2.13E-05 1.46
rs11849413 14q21.2 45185079 C14orf28 C 2.14E-05 1.97
rs9268645 6p21.32 32408527 HLA-DRA G 2.31E-05 1.42
rs1419671 6p22.1 30097170 TRIM40 A 2.37E-05 1.48
rs9261468 6p22.1 30104480 TRIM40 G 2.38E-05 1.48
rs6457620 6p21.32 32663999 HLA-DQA2 C 2.47E-05 1.43
rs75059452 5q34 167700090 TENM2 A 2.52E-05 1.63
rs2523685 6p21.33 31426256 MICA G 2.53E-05 1.61
rs7510817 22q11.22 23281338 IGLL5 C 2.56E-05 1.75
rs7759742 6p21.32 32381736 HLA-DRA A 2.57E-05 1.43
rs2280800 6p21.33 31646398 LY6G5C A 2.67E-05 1.60
rs2239689 6p21.33 32030284 TNXB A 2.69E-05 1.43
rs59726684 8p21.2 24775457 NEFM C 3.00E-05 2.69
rs60158447 19q13.32 46387792 IRF2BP1 C 3.14E-05 4.24
rs9261535 6p22.1 30127323 TRIM10 A 3.17E-05 1.47
rs77637983 6p21.32 32549452 HLA-DRB1 C 3.23E-05 1.44
rs1557611 6p22.1 30118360 TRIM10 T 3.39E-05 1.47
rs7328468 13q32.1 96135266 CLDN10 A 3.42E-05 1.42
rs1264585 6p22.1 30285650 HCG18 A 3.51E-05 1.46
Affx-37072023 6p21.32 32612430 HLA-DQA1 C 3.66E-05 1.43
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rs2239530 6p22.1 30152115 TRIM26 G 3.66E-05 1.47
rs387608 6p21.33 31941557 STK19 G 3.74E-05 1.93
rs1541267 6p22.1 30103571 TRIM40 G 3.77E-05 1.45
rs149401094 6p21.32 32374906 HLA-DRA T 3.78E-05 6.82
rs2187818 6p21.32 32395568 HLA-DRA T 3.81E-05 1.41
Affx-52344168 8p23.1 7681330 DEFB105B A 3.82E-05 12.51
rs9271709 6p21.32 32593392 HLA-DRB1 G 3.85E-05 1.48
rs2278319 8p21.2 27308961 PTK2B T 4.01E-05 1.44
rs2523467 6p21.33 31362930 MICA C 4.09E-05 1.48
rs4711211 6p22.1 30162809 TRIM26 G 4.44E-05 1.46
rs4835669 5q31.2 137473391 NME5 A 4.74E-05 1.41
rs6457617 6p21.32 32663851 HLA-DQA2 T 4.77E-05 1.41
rs2022533 6p21.32 32307260 C6orf10 G 4.86E-05 1.41
rs2844529 6p21.33 31353593 MICA G 4.94E-05 1.47
Affx-52368679 6p21.32 32632863 HLA-DQB1 CGGT 5.01E-05 1.44
rs2734971 6p22.1 29834449 HLA-G A 5.19E-05 1.40
Affx-28427568 6p22.1 30313268 TRIM39-RPP21 A 5.40E-05 1.44
rs2523473 6p21.33 31361897 MICA A 5.48E-05 1.47
rs8090342 18p11.22 9872638 RAB31 G 5.54E-05 1.75
rs56178414 7q32.2 129201085 SMKR1 A 5.63E-05 1.62
rs2071293 6p21.33 32062687 TNXB A 5.87E-05 1.41
rs148222739 6q16.1 96034467 MANEA A 5.87E-05 17.55
rs12874536 13q13.3 38332015 TRPC4 T 6.19E-05 1.41
rs928822 6p22.1 30275246 HCG18 G 6.28E-05 1.40
rs56042230 11q24.1 123347461 GRAMD1B A 6.52E-05 1.63
rs1115928 18q12.1 28208468 DSC3 A 6.67E-05 1.45
rs3020644 6p21.33 31894626 C2 G 6.68E-05 1.40
rs28366130 6p21.33 31363805 MICA A 6.78E-05 1.47
rs2596542 6p21.33 31366595 MICA C 6.89E-05 1.46
rs34171662 6p22.1 30285524 HCG18 T 7.09E-05 1.94
rs74356372 1p34.1 44931239 RNF220 G 7.75E-05 1.41
rs6929776 6p21.32 32303511 C6orf10 A 7.79E-05 1.39
rs614549 6p21.33 31840625 SLC44A4 G 7.80E-05 1.39
rs438999 6p21.33 31928306 SKIV2L A 7.87E-05 2.16
rs3806156 6p21.32 32373698 BTNL2 T 8.02E-05 1.39
Affx-28465058 6p21.33 31936679 SKIV2L C 8.28E-05 1.86
rs4756952 11p15.1 18589236 UEVLD C 8.36E-05 1.45
rs61997250 16q21 58001086 CNGB1 T 8.51E-05 2.14
rs9275857 6p21.32 32691308 HLA-DQA2 C 8.54E-05 1.45
rs3819721 6p21.32 32804798 TAP2 A 8.60E-05 1.42
rs7377975 4p16.1 6200070 JAKMIP1 A 8.62E-05 1.45
rs146599962 18q21.31 55398906 ATP8B1 G 8.78E-05 18.49
rs541862 6p21.33 31916951 CFB T 8.88E-05 2.15
rs115278773 4p16.3 437909 ZNF721 C 9.33E-05 3.26
rs7759909 6p21.33 31158689 PSORS1C3 G 9.37E-05 1.93
rs4729707 7q22.1 101070104 COL26A1 T 9.42E-05 1.39
rs9911245 17q25.3 77327398 RBFOX3 A 9.47E-05 1.39
Legend: Association data are shown for all SNPs achieved Eigenstrat P values < 1.0 x 10-4.
Affymetrix SNP IDs are provided for SNPs with no available rs ID.
ANCA = anti-neutrophil cytoplasmic antibody; MPO = myeloperoxisase; pANCA = perinuclear ANCA
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rs141530233 6p21.32 HLA-DPB1 A del 1.13E-89 2.99 1.47E-03 2.32 5.71E-01 1.06 2.02E-01 1.13
rs1042169 6p21.32 HLA-DPB1 G 1.12E-84 2.82 5.55E-05 2.72 2.61E-01 1.11 3.18E-01 1.10
rs9277341 6p21.32 HLA-DPA1 T 6.09E-71 2.44 6.09E-03 2.02 1.60E-01 1.14 8.15E-03 1.28
rs35242582 6p21.32 HLA-DQA1 A 6.34E-23 1.60 7.39E-01 1.10 2.88E-01 1.10 2.10E-01 1.11
rs1049072 6p21.32 HLA-DQB1 A 6.46E-13 1.40 5.02E-01 1.21 9.89E-01 1.00 1.30E-01 1.13
rs6679677 1p13.2 PTPN22 A 1.88E-08 1.40 2.34E-01 1.60 8.30E-01 1.02 8.30E-01 1.02
rs62132293 19p13.3 PRTN3 G 8.60E-11 1.29 6.32E-01 1.11 7.77E-01 1.02 1.80E-01 1.10
rs28929474 14q32.13 SERPINA1 T 3.09E-12 2.18 4.27E-01 1.76 6.81E-01 1.07 1.12E-01 1.33
rs2476601 1p13.2 PTPN22 (R620W) A 1.86E-07 1.36 2.33E-01 1.60 8.02E-01 1.03 9.44E-01 1.01
Legend: ANCA = Anti-neutrophil cytoplasmic autoantibody; PR3 = proteinase 3; MPO = myeloperoxidase; N = numbers of subjects; OR = odds ratio; P = Eigenstrat P value.
ANCA positivea = positive for at least one of PR3-ANCA, cANCA, MPO-ANCA, and pANCA.
ANCA negativeb = negative for all of PR3-ANCA, cANCA, MPO-ANCA, and pANCA.
Overall analysis of combined cohort 
(N = 1986 cases, 4723 controls)
Supplementary Table 7. Effects of organ involvement and ANCA status on MHC and non-MHC associations with ANCA-associated vasculitis.
Organ involvement
Lung affected (N = 1200) vs    
Lung not affected (N = 616)
Kidney affected (N = 1171) vs   
Kidney not affected (N = 642)
ANCA positivea (N = 1739) vs  
ANCA negativeb (N = 42)
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P OR (95% CI)  P OR (95% CI)
Primary cohort HLA-DPB1 rs141530233 5.93E-56 2.76 (2.44 - 3.13) 9.76E-35 2.31 (2.02 - 2.63)
HLA-DPA1 rs9277341 1.62E-40 2.21 (1.96 - 2.50) 2.84E-15 1.65 (1.46 - 1.87)
HLA-DQA1 rs35242582 3.34E-16 1.61 (1.43 - 1.79) 2.74E-12 1.52 (1.35 - 1.71)
PR3-ANCA/cANCA subgroup HLA-DPB1 rs141530233 1.69E-68 6.06 (4.95 - 7.41) 2.73E-50 4.94 (4.00 - 6.09)
HLA-DPA1 rs9277341 3.91E-50 3.44 (2.92 - 4.05) 1.64E-20 2.24 (1.89 - 2.66)
MPO-ANCA/pANCA subgroup HLA-DQA2 rs3998159 3.47E-19 2.61 (2.12 - 3.22) 2.15E-03 1.65 (1.20 - 2.27)
HLA-DQB1 rs1049072 1.63E-18 2.27 (1.89 - 2.72) 2.05E-04 1.70 (1.28 - 2.25)
Legend: OR = odds ratio; 95% CI = 95% confidence interval; ANCA = anti-neutrophil cytoplasmic antibody; PR3 = proteinase-3; MPO = myeloperoxidase.
a Data are from results of genome-wide association study (GWAS) incorporating total cohort or PR3-ANCA/cANCA or MPO-ANCA/pANCA subgroups
b Peak SNP from GWAS
Supplementary Table 8. Conditional analyses of risk alleles across the HLA locus
Unconditioned Conditioned
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eSupplementary Table 9. Evaluation of genetic models for susceptibility for ANCA-associated vasculitis.
SNP Gene Region Genetic Model 2* Ln Likelihood
Degrees of 
freedom Test statistic (p -value) OR (95% CI)
rs141530233 HLA-DPB1 General 5068.76 2
Dominiant 5358.73 1 289.97 (5.06 x 10-65) 2.29 (1.71, 3.07)
Recessive 5068.84 1 0.08 (7.79 x 10-1) 3.59 (3.10, 4.15)
rs9277341 HLA-DPA1 General 5318.00 2
Dominiant 5488.80 1 170.80 (4.95 x 10-39) 2.44 (1.82, 3.27)
Recessive 5321.13 1 3.13 (8.00 x 10-2) 2.69 (2.34, 3.08)
rs35242582 HLA-DQA1 General 5538.26 2
Dominiant 5611.73 1 73.47 (1.02 x 10-17) 1.47 (1.10, 1.98)
Recessive 5538.26 1 0.001 (9.80 x 10-1) 1.82 (1.60, 2.09)
Legend: Analyses are derived from fitting logistic regression models to data and comparing the log likelihood ratio of a full model with 
parameters for additive allelic effects and a recessive effect to reduced models that comprised either recessive or dominant models. In all cases, 
the recessive model was not rejected indicating it is the best fitting model. 
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Locus Gene Peak SNP Location P value Peak SNP Location P value
a. AAV 1p13.2 PTPN22 rs6679677 114303808 2.40E-08 rs6679677 114303808 5.62E-08
6p21.32 HLA-DPB1 rs141530233 33048688 5.93E-56 rs141530233 33048688 1.18E-61
6p21.32 HLA-DPA1 rs9277341 33039625 1.62E-40 rs9277341 33039625 5.83E-46
6p21.32 HLA-DQA1 rs35242582 32600057 3.34E-16 rs114567049 32601719 1.30E-19
6p21.32 HLA-DQB1 rs1049072 32634355 4.23E-10 rs28746835 32633959 4.35E-17
14q32.13 SERPINA1 rs28929474 94844947 8.26E-08 rs28929474 94844947 9.86E-08
19p13.3 PRTN3 rs62132293 838178 5.55E-08 rs138303849 837174 2.84E-10
b. MPO/pANCA 6p21.32 HLA-DQA2 rs3998159 32682019 3.47E-19 rs55765078 32647433 1.70E-20
6p21.32 HLA-DQB1 rs1049072 32634355 1.63E-18 rs28746838 32634057 4.10E-20
Legend: ANCA = anti-neutrophil cytoplasmic antibody; AAV = ANCA-associated vasculitis; MPO = myeloperoxidase.
Observed Imputed
Supplementary Table 10. Comparison of peak observed SNPs and peak imputed SNPs at risk loci for (a) ANCA-
associated vasculitis, (b) MPO-ANCA/pANCA associated vasculitis.
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1p13.2 PTPN22 rs2476601 114377568 index 0.7876 nonsynonymous variant: R620W - -
rs6679677 114303808 0.99 0.2123 upstream gene variant - -
6p21.32 HLA-DPB1 rs141530233 33048688 index 0.9998 nonsynonymous variant: G85E HLA-DPB1 -
rs1042169 33048686 1.00 0.9201 nonsynonymous variant: G84D HLA-DPB1 LCLs
rs386699872 33048694 1.00 0.0793 nonsynonymous variant: M87V HLA-DPB1 LCLs
6p21.32 HLA-DPA1 rs9277341 33039625 index 0.9983 intron variant HLA-DPA1, HLA-DPB1 Monocytes
6p21.32 HLA-DQA1 rs35242582 32600057 index 0.8952 upstream gene variant HLA-DQB1 LCLs
rs34180045 32600066 0.90 0.0361 upstream gene variant





6p21.32 HLA-DQA2 rs3998159 32682019 index 0.0997 upstream gene variant HLA-DQA2 LCLs
rs7454108 32681483 1.00 0.0997 upstream gene variant HLA-DQA2 LCLs
rs3957148 32682137 1.00 0.0997 upstream gene variant HLA-DQA2 LCLs
rs3957146 32681530 1.00 0.0997 upstream gene variant HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRB6 LCLs
rs9275583 32680299 0.99 0.0557 upstream gene variant - -
rs9275592 32680620 0.97 0.0431 upstream gene variant HLA-DQA2 LCLs
rs4273728 32678491 0.97 0.0431 upstream gene variant - -
14q32.13 SERPINA1 rs28929474 94844947 index 0.9758 nonsynonymous variant: E366K (Z allele) - -
19p13.3 PRTN3 rs62132293 838178 index 0.4596 upstream gene variant - -
rs62132296 841100 0.92 0.0816 intron variant - -
rs62132295 840448 0.92 0.0816 upstream gene variant - -
rs3826947 839876 0.91 0.0754 upstream gene variant - -
rs62132294 839298 0.88 0.0470 upstream gene variant - -
rs62132289 837863 0.87 0.0448 upstream gene variant - -
rs2301879 843692 0.85 0.0365 regulatory gene variant - -
rs3729642 839562 0.85 0.0365 upstream gene variant - -
Supplementary Table 11. Most-likely disease causal variants identified by functional annotation.
eQTL
Legend: Candidate variants at AAV and MPO-ANCA risk loci with probabilistic identification of causal SNPs (PICS) probability > 0.0275 identified using the online PICS 
algorithm (http://www.broadinstitute.org/pubs/finemapping/?q=pics). The functional consequence of each variant was predicted using the Ensembl Variant Effect Predictor (VEP) 
web tool (http://www.ensembl.org/Homo_sapiens/Tools/VEP). Cis eQTLs were identified using the following searchable eQTL browsers and databases: 1) eqtl.uchicago.edu 
(http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/), 2) seeQTL (http://www.bios.unc.edu/research/genomic_software/seeQTL) and 3) GTEx Portal (http://www.gtexportal.org/home/ 
eqtls/tissue?tissueName=All).  eQTL = expression quantitative trait locus; PBs = peripheral blood cells; SNP = single nucleotide polymorphism; LCL = lymphoblastoid cell lines; 
MAF = minor allele frequency.
Locus SNP Position
r2 with 
peak SNP PICS Functional consequence
Implicated 
Gene
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